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Engineered nanomaterials that produce reactive oxygen species on exposure
to X- and gamma-rays used in radiation therapy offer promise of novel cancer
treatment strategies. Similar to photodynamic therapy but suitable for large
and deep tumors, this new approach where nanomaterials acting as
sensitizing agents are combined with clinical radiation can be effective at
well-tolerated low radiation doses. Suitably engineered nanomaterials can
enhance cancer radiotherapy by increasing the tumor selectivity and
decreasing side effects. Additionally, the nanomaterial platform offers
therapeutically valuable functionalities, including molecular targeting,
drug/gene delivery, and adaptive responses to trigger drug release. The
potential of such nanomaterials to be combined with radiotherapy is widely
recognized. In order for further breakthroughs to be made, and to facilitate
clinical translation, the applicable principles and fundamentals should be
articulated. This review focuses on mechanisms underpinning rational
nanomaterial design to enhance radiation therapy, the understanding of
which will enable novel ways to optimize its therapeutic efficacy. A roadmap
for designing nanomaterials with optimized anticancer performance is also
shown and the potential clinical significance and future translation are
discussed.
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1. Introduction
Cancer is a complex disease whose treat-
ment requires individually tailored modal-
ities such as surgery, radiation therapy,
chemotherapy, immunotherapy, and photo-
dynamic therapy.[1,2] Many of these thera-
pies have well-known side effects, such as
drug toxicity in the case of chemotherapy[3,4]
and/or fibrosis or induction of late can-
cers in the case of radiation therapy.[5,6]
Minimizing these off-target effects repre-
sents an ongoing challenge.[7–9] The po-
tential for synergistic effects and dose re-
duction by combining treatment modali-
ties, especially with radiotherapy that is
used in ≈50% of cancer patients,[10] has
led to interest in combinational therapy
approaches.[11] These include radiosensiti-
zation, i.e., the use of various chemical
agents that make cells more responsive to
radiation therapy,[12] aspects of which are
discussed in this review. The efficacy of ra-
diosensitizers is measured in terms of in-
creased cancer cell kill while normal tissue
function is retained. Thus, it is desirable that the radiosensitizers
act differently in cancer and noncancer cells, rather than simply
ensuring an overall amplification of the radiation dose.
Spatial and temporal control of treatment delivery is key
in nonsurgical modalities of cancer treatment. Both radiother-
apy, with its sophisticated treatment planning, and emerging
modalities such as high intensity focussed ultrasound[13,14] pro-
vide excellent but not yet perfect spatial localization.[15–17] Fur-
ther improvement in tumor selectivity is promised by molecu-
larly targeted nanoformulated agents[18,19] including those with
enhanced functionalities.[20,21] Hence, combining radiotherapy
and cancer-targeted nanoparticle (NP) formulations is a log-
ical step to more efficient cancer therapies, expected to of-
fer expanded cancer treatment options and/or improved ther-
apeutic efficacy. The uses of NPs in cancer treatment, includ-
ing in radio-oncology, have been reviewed previously,[15,22–36]
while multimodal synergistic cancer therapies were extensively
summarized elsewhere.[11,26–30] Significant caveats are that ef-
fective delivery of nanomaterials to tumor is still suboptimal
and, ideally, treatment should not only destroy the primary tu-
mor but also reduce the risk of recurrence. In addition, the
use of such combined treatments must be aligned with clinical
workflows.
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Figure 1. Illustration of physical, chemical, biochemical/biomolecular, and biological effects taking place in cells and tissues upon exposure to ionizing
radiation. CR: Cherenkov radiation; ROS: reactive oxygen species; RNS: reactive nitrogen species.
X-ray induced photodynamic therapy (X-PDT) is a recently de-
veloped approach for cancer therapy which utilizes X-ray as an
energy source to activate reactive oxygen species (ROS) genera-
tion similarly to PDT where cytotoxicity is also due to the induc-
tion of ROS.[27,37,38] Photodynamic therapy utilizes photosensi-
tizer (PS) drugs that are designed to be activated by light in the
presence of oxygen in the tissue to produce ROS that are cyto-
toxic. In X-PDT, ROS are produced by X-PDT agents that are ac-
tivated by X-rays instead of light, allowing much deeper tissue
penetration of X-PDT than traditional PDT. The X-PDT agents in-
vestigated to-date almost exclusively comprise specially designed
NPs, although this is not a critical requirement. X-PDT can be
regarded as a unique radiosensitizing method, where radiosen-
sitization occurs due to increased generation of reactive oxygen
species.[39] It is worth mentioning that some of the published lit-
erature uses the term radiodynamic therapy (RDT) referring to
the situation where ionizing radiation (X-ray) is used to excite a
sensitizing agent.[40–42] This term tends to be used when the sen-
sitizing agent is a molecule. Here, we will use the term X-PDT
referring to the use of X-rays to excite sensitizing agents regard-
less of their molecular or NP character (see Section 7 for more
clarifications of terminology used in this field).
In this review, we focus on the rarely discussed physicochem-
ical basis for X-PDT radiosensitization,[10] and the opportunities
and limitations thereof, some of which draw on understanding of
how ionizing radiation interacts with cells and tissues. In addi-
tion to DNA damage and antioxidant response, other cellular pro-
cesses and mechanisms respond to radiation.[12] These may offer
suitable additional targets or bottlenecks that could be addressed
by a suitable tailoring of the nanomaterials, and which may vary
across cancer types. We further discuss the opportunities for op-
timizing the generation of cytotoxic free radicals by combining
radiotherapy with tailored nanomaterials and consider the pro-
cesses in cancer cells and tissues exposed to such combinatorial
treatments including defence mechanisms. In discussing these
topics, we identify the potential opportunities in materials sci-
ence and some of the issues at the intersection of materials sci-
ence and cell biology that are addressable by judicious nanoma-
terials engineering.
In order to limit the scope of this review, we do not cover is-
sues related to NP delivery and tumor uptake, nor the processes
that NP undergo in cells and organisms such as clearance, the ef-
fectiveness of the enhanced permeability and retention (EPR) ef-
fect on NP accumulation, and the stability of NPs in blood which
have been expertly reviewed elsewhere.[43–50] Finally, we also do
not discuss biological factors that impact cellular resilience to ox-
idative stress, or the intrinsic radiosensitivity of specific cell and
tissue types[51] that have also been reviewed.[52,53]
The paper is organized as follows. In Sections 2 and 3 we dis-
cuss the cascade of physical, chemical, and biological events in
cells and tissues exposed to ionizing radiation that affect their
function, as illustrated in Figure 1, and point to potential molec-
ular targets for nanomaterials. Of specific interest are cellular sys-
tems of protection against oxidative stress that should be selec-
tively disabled by prospective nanomaterial radiosensitizers. We
focus on DNA damage and its repair, as well as on maintaining
the redox status through the cellular antioxidant system. We also
explore mechanisms of radiosensitization and ways that they can
be modulated by radiosensitizers and exploited using designed
nanomaterials.
We then discuss the interaction of radiation and engineered
NPs that lead to the generation of reactive oxygen species, as il-
lustrated in Figure 2. Section 4 centers on the interaction of NPs
with radiation and related physical and chemical effects. The dis-
cussion is developed through the lens of catalytic processes at
solid surfaces. Drawing on analogies between photo- and radio-
catalysis, we suggest future developments of the X-PDT field that
build on selected advances in the areas of clean energy, water
splitting, and environmental remediation. In Section 5 we focus
on nanomaterials in which the coatings contain clinically used
PSs, which offer additional opportunities for maximizing the ef-
ficacy, by utilizing the transduction of ionizing radiation into vis-
ible light or the Cherenkov light generated in tissue by the pas-
sage of ionizing radiation. Section 6 discusses example particle
designs that include PSs and their interaction with radiation. Fo-
cusing on future clinical translation, we discuss biocompatible
nanocarriers (liposomes and poly(lactic-co-glycolic acid) (PLGA)
NPs) as well as mesoporous silica and point to novel opportuni-
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Figure 2. Interaction of radiation with NP constructs.
ties related to aggregation-induced emission. Section 7 clarifies
the issue of somewhat fluid terminology used in the field. Finally,
in Sections 8 and 9 we draw a roadmap of future development
in this field and discuss the opportunities and challenges in the
translation of X-PDT into clinical oncological practice.
2. Interaction of High Energy Electromagnetic
Radiation with Materials: Physical and Chemical
Mechanisms
2.1. Primary Molecular Damage Induced by Ionizing Radiation
The term “ionizing radiation” refers to electron, proton, and neu-
tron beams or electromagnetic radiation with high enough en-
ergy to ionize atoms and molecules. High energy electromagnetic
radiation is conventionally referred to as X-rays if they have en-
ergy higher than ≈12–120 eV (100–10 nm wavelength), and we
remind that visible light is also a form of electromagnetic radia-
tion but with energies in the range of 1.8 to 4.1 eV (700 to 300 nm
wavelength). If the electromagnetic rays are generated via a nu-
clear decay, they are typically referred to as gamma (𝛾) rays.[54]
Clinical radiotherapy uses either external X-ray beams, nowadays
mostly high-energy (up to about 20 MeV) from linear accelera-
tors, or internal radioactive implants (brachytherapy), depending
upon the location and type of tumor. Interactions of these X-rays
with atoms in the tissue[55,56] result in a cascade of secondary
photoelectrons and Auger electrons. These disrupt atomic and
molecular structures along the radiation track, eventually dissi-
pating their energy and leaving in their wake a pool of reactive
and potentially cytotoxic molecular species, including (thermal-
ized) hydrated electrons, free radicals, and various excited-state
ions and molecules. X-rays have a low LET of 0.2–0.3 keV µm−1,
compared, for example, with alpha particles which have high LET
≈140 keV µm−1.[57] The penetration depth of ionizing radiation
is inversely related to its LET,[58] as and the value of LET plays
a significant role in the induction of cellular damage. High LET
radiation causes more extensive cellular damage, but it does not
penetrate as deeply into the body as low LET radiation that is typ-
ically used to treat deep-seated tumors. The radiation dose, D,
in tissue is expressed in Grays (Gy), where 1 Gy = 1 J of energy
absorbed per kg of tissue mass.[59] In order to account for differ-
ent biological effects of ionizing radiation with varying LET, the
concept of “equivalent dose” is also used. The equivalent dose is
measured in units of Sieverts (Sv), and it is given by the product
of D and a dimensionless quality factor, Q, that depends on the
LET.
Many of these constituents are transient, with sub-µs
lifetimes.[57] Since water is the main constituent of cells and
tissues by mass (>80%), the primary effect of X-rays is radiol-
ysis of water to produce radiolytic products.[57,60] The balance
of radiolytic products (e−aq, H
•, HO•, HO∙2, OH
−, H3O
+, H2,
H2O2) depends on the linear energy transfer (LET) of the radi-





X-rays have a low LET of 0.2–0.3 keV µm−1, compared, for exam-
ple, with alpha particles which have high LET ≈140 keV µm−1.[57]
The penetration depth of ionizing radiation is inversely related to
its LET,[58] as and the value of LET plays a significant role in the
induction of cellular damage. High LET radiation causes more ex-
tensive cellular damage, but it does not penetrate as deeply into
the body as low LET radiation that is typically used to treat deep-
seated tumors. The radiation dose, D, in tissue is expressed in
Grays (Gy), where 1 Gy = 1 J of energy absorbed per kg of tissue
mass.[59] In order to account for different biological effects of ion-
izing radiation with varying LET, the concept of “equivalent dose”
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Figure 3. Main molecular events during radiolysis of water and key radiolytic products (e−aq, H
∙, HO∙, HO∙2, OH
−, H3O
+, H2, H2O2). Adapted with
permission under the Creative Commons Attribution License.[57] Copyright 2011, MDPI.
is also used. The equivalent dose is measured in units of Sieverts
(Sv), and it is given by the product of D and a dimensionless qual-
ity factor, Q, that depends on the LET.
2.2. Light Generation by Radiation: Cherenkov Effect
The passage of high-energy secondary electrons generated by the
MeV range radiation through a dielectric medium such as tissue
can also generate Cherenkov light (CL).[61,62] This requires X-rays
(or gamma rays) of energy higher than the Cerenkov threshold
(ET), whose value in tissue is 219 keV.
[63–65] In vacuum CL has
a broad spectrum that varies as a function of wavelength, 𝜆, as
𝜆−2.[66] Due to light absorption and scattering in tissue and its
components (water, hemoglobin, lipids), the effective CL spec-
trum in tissue has a complex shape, with a maximum around
650 nm.[67–70]
The estimated photon yield of the Cherenkov process from
clinical radionuclides is rather low, ≈1–50 photons per decay, cor-
responding to ≈12 000 photons per Bq for 18F and ≈199 000 for
68Ga.[66] The Cherenkov photon yield from 5 to 20 MeV X-ray pho-
ton beams is 60–100 photons per deposited MeV of energy.[66]
The latter value can be related to the radiation dose where for
1 Gy radiation dose, ≈5 × 1011 Cherenkov photons are generated
per cm3 of tissue. Correspondingly, the CL intensity reported in
the literature is low (≈0.01–1 nW cm−2 per MBq g−1 for radionu-
clides, and 1–100 µW cm−2 per Gy s−1 for external radiotherapy
beams).[70] Despite this weakness of the CL, several authors have
attributed an improved anticancer effect of their nanomaterials
combined with radioisotopes to a Cherenkov process.[66,71,72]
Table 1. Radiolytic yield, half-life and approximate migration distance of
main radiolysis products in water. The radiolytic yield (G value) represents
the number of molecules created or destroyed per 100 eV of energy de-
posited in the system and half-life is the time required for a quantity to
reduce to half of its initial value.
Radiolytic
product
Migration distance [m] Half-life [s] Radiolytic yield
[µmol J−1]
HO• 4 × 10−9–6 × 10−9[74] 10−9[79] 0.28[57]
H• 9 × 10−9–4 × 10−7[74] 10−9[74] 0.06[57]
H2O2 1 × 10−6[75] 10−3[76] 0.063[57]
e−aq 1 × 10
−6–2 × 10−6[74] 2 × 10−5–8 × 10−4[77] 0.28[57]
2.3. Primary Chemically Active Species Generated by Ionizing
Radiation
The secondary electrons produced by ionizing radiation are
highly reactive and generate multiple radiolytic products, either
directly or indirectly.[57,73] The molecular events during the radi-
olysis of water are described in Figure 3. The main products of
low-LET radiation in water are e−aq (hydrated electrons), HO
• (hy-
droxyl radicals), H• (hydrogen radicals), H2 (radiolytic hydrogen),
H2O2 (hydrogen peroxide), and HO
∙
2 (hydroperoxyl radical) (see
Table 1 for radiolytic yields[57]).
H2O2 is the only stable product of radiolysis, while the other
products are transient; e.g., the half-life of HO•is ≈10−9 s.[78,79]
H2 is not relevant for radiotherapy, as it escapes from the aque-
ous solution, whereas e−aq and H
• convert oxygen to O−2 (super-
oxide) or HO∙2 radicals, the latter being present in only negligi-
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ble amounts for low-LET radiation.[57] Consequently, HO•, H2O2,
and oxygen level-dependent O−2 are the main ROS formed in cells
during low-LET radiolysis of water,[57,60,80] while e−aq and H
• are
also transiently present and limited by the concentration of avail-
able oxygen.
Representative one-electron redox reactions generating some
of these products, and the associated reduction potentials 𝜖′, are
given by[81]
O2 + e− → O−2 , 𝜀
′ = −0.33 V (2)
O−2 + 2H
+ + e− → H2O2, 𝜀′ = +0.89 V (3)
H2O2 + H+ + e− → H2O + HO∙, 𝜀′ = +0.38 V (4)
The cited values are relative to the potential of a neutral hydro-
gen electrode and at pH = 7.
The key radiolytic products in water are the same as the main
physiological ROS generated in cells,[78] but their absolute and
relative concentrations differ. In particular, in low-LET irradia-
tion of cells, HO• is the most abundant ROS, while O−2 and H2O2
are the key species produced by endogenous processes in cells
through multiple mechanisms.[60] There are further differences
in the dynamics between ROS that are physiologically generated
and those created by water radiolysis, in particular ROS bursts
and clustering of radiation damage is found in cells exposed to
X-ray radiation, compared with a more homogeneous distribu-
tion of endogenous physiologically generated ROS.[60]
On average, about 30 eV of energy is required to generate a sin-
gle ROS radical by radiolysis of water.[82] Hence, a short (<1 µs)
burst of about 200 ROS is created by a single low LET X-ray pho-
ton depositing ≈6 keV µm−1 in a 20 µm long track within a cell.[82]
By contrast, the ROS generation rate from cellular metabolism is
some three orders-of-magnitude lower, at ≈105 ROS per second
per cell.[82]
The primary products of water radiolysis are readily converted
in cells into further reactive species. For example, superoxide can
react with molecular hydrogen to generate hydrogen peroxide[83]
2O−2 + 2H → H2O2 (5)
The primary ROS, especially HO•, then react further to create
organic radicals (R•) and, by a subsequent rapid reaction with
O2, strongly oxidizing peroxyl radicals (RO
∙
2). These reactive inter-
mediates then interact with available H• to form hydroperoxides
(ROOH).[60]
Hydrated electrons produced in water radiolysis are very pow-
erful reductants capable, for example, of reducing metal ions that
may then react further with oxygen, giving rise to superoxide
Mered
n+ + O2 ↔ Meox
(n+1)+ + O−2 (6)
Radiolytically generated hydrogen peroxide, H2O2, in the pres-
ence of redox-active metals such as iron, copper, manganese or
zinc ions present in cells that serve as catalysts may form free
hydroxyl radicals through the Fenton, Fenton-like or the Haber–
Weiss cycle reactions.[84] The Fenton reaction generates hydroxyl
radicals and increases the charge state of metal ions according to
the following reaction
Fe2+ + H2O2 → Fe3+ + HO∙ + OH− (7)
Similarly, Fenton-like reactions increase the charge state of
copper to produce hydroxyl radicals
Cu+ + H2O2 → Cu2+ + HO∙ + OH− (8)
The Haber–Weiss cycle reaction generates hydroxyl radicals
from H2O2 and superoxide anions, while the metal ions are cy-
cled between their charged states
O−2 + H2O2 → ∙OH + OH
− + O2 (9)
Furthermore, radiolytically generated ROS may react with
nitric oxide radicals (NO•) that are endogenously abundant
in cells.[78] These radicals have half-lives of a few seconds in
an normoxic aqueous environment and >15 s in a hypoxic
environment.[78] NO• combines, for example, with a superoxide
anion to form peroxynitrite anion (ONOO−)
NO∙ + O−2 → ONOO
− (10)
This is a potent oxidant that can further bind with transition
metal ions such as iron and copper.[78] This and other reactive
nitrogen species (RNS) elicit further damage in cells, such as lipid
peroxidation and damage to proteins and DNA.[60,85]
The products of radiolysis may also enter further biochemical
enzymatic reactions in cells enabled by cellular mechanisms that
maintain homeostasis of endogenous ROS species. For example,
the superoxide in cells is converted by superoxide dismutase into
hydrogen peroxide and singlet oxygen (1O2).
[86]
The half-lives of some ROS/RNS generated by light and/or ra-
diation, in particular for hydroxyl radicals and 1O2 are very short
(<1 µs), so that they act very locally, typically within tens of nm
from the generation site.[87] The much lower reactivity of H2O2
and O−2 and longer half-lives allow them to diffuse further from
the site of origin to other cellular compartments.
The short life of the ROS/RNS makes their detection challeng-
ing. Direct approaches, such as electron paramagnetic (EPR)
spectroscopy and near-infrared luminescence spectroscopy are
limited by the short half-lives so that observation is possible
only on a sub-ms time scale,[88] and typical low concentra-
tions. Near-infrared spectroscopy detection is based on the
luminescent emission of 1O2 at 1270 nm, which is very weak
(due to competing de-excitation pathways of biomolecular
interactions), leading to low sensitivity.[88–90] Alternative but
indirect methods use high-sensitivity probes[91,92] suitable for
fluorimetry or fluorescence imaging;[93,94] these overcome the
short lifetimes and low concentration limitations.[95] Com-
monly used probes include 1,3-diphenyl isobenzofuran (DPBF),
9-[2(3-carboxy-9,10-dimethyl)anthryl]-6-hydroxy-3H-xanthen-3-
one(DMAX),9-[2-(3-carboxy9,10-diphenyl)anthryl]-6-hydroxy-
3H-xanthen-3-one(DPAX), singlet oxygen sensor green (SOSG:
dichlorodihydrofluorescein), and hydroethidine, as well as di-
hydrorhodamine and chemiluminescent methods[96,97] are also
used. •OH radicals can be quantified using coumarin scav-
enging, where the resulting 7-hydroxycoumarin fluorescence
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is measured.[98,99] Hydrated electrons can be been quantified
by determining the •OH generation measured under N2O
atmosphere and comparing it to the value obtained under N2.
[99]
The main advantages of using chemical probes compared to
direct methods are their strong signals and the corresponding
ease of fluorescence detection in the visible spectral range.
Drawbacks include the need to use an additional exogenous
(and potentially toxic) materials, the possibility of generating
additional reactive photoproducts, and the confounding effects
of the microenvironment.[99] Nosaka and Nosaka[100] provide an
extensive summary of the available ROS detection methods.
3. Interaction of Radiation with Cells and Tissues:
Biological Effects
3.1. Reactions of Radiolysis Products with Biomolecules in Cells
Low energy electrons such as e−aq, free radicals with unpaired elec-
trons, as well as other secondary reactive oxygen and nitrogen
species, show variable reactivity toward critical components of
cells.[60] For example, superoxide is a poor oxidant with low reac-
tivity, in contrast to the hydroxyl radical which is highly reactive
due to its unpaired spin.[101] These different species may cause
lipid peroxidation or protein denaturation.[78,101,102] Their interac-
tions with nucleic acids can induce structural DNA damage (nu-
clear and mitochondrial), such as single or double strand breaks
(SSB, DSB), as well as crosslinking and telomere dysfunction,
particularly when damage clusters are formed. The DNA dam-
age mediated by low energy electrons is initiated by electron ex-
citation in DNA molecules which leave behind positively charged
holes. These migrate along the DNA molecule, accumulating
mainly in guanine, which has the lowest ionization potential
among all nucleobases, and the ensuing base damage, assisted by
endonuclease and glycosylase, produces strand breaks.[103] Two
thirds of the total DNA damage is due to low energy electrons
and the remainder is caused by the interaction with ROS.[104]
The reactivity and/or generation of free radicals may be en-
hanced by exogenous drugs such as chemotherapy agents and
radiosensitizers.[16,54,105–107] For example, the incorporation into
DNA of platinum complexes such as cisplatin, oxaliplatin or car-
boplatin can increase the reactivity of low-energy electrons by a
factor of 2–4, which enhances the radiotherapeutic efficacy. Anti-
cancer drugs such as doxorubicin, epirubicin, and daunorubicin
also act as ROS-generating agents in their own right.[84]
Given the significance of cellular DNA damage, efforts
have been expended to optimize it, for example, by nu-
clear radiosensitization[108] or by targeting NPs directly to the
nucleus[109] using cell-penetrating peptides (CPPs), such as trans-
activating transcriptional activator from human immunodefi-
ciency virus 1 (TAT), nuclear localization sequence or arginylgly-
cylaspartic acid (RGD) peptides.[110–112] Nanocarriers with such
targeting moieties can deliver biologically active cargoes (drugs,
genes, antibodies, imaging agents, etc.) and even other small NPs
to the nucleus.[113] For example, nuclear targeting of gold NPs
with TAT peptide resulted in a radiation sensitization enhance-
ment ratio (SER) of 2.3.[114] Alternatively, 7-Ethyl-10-hydroxy-
camptothecin (SN-38) has been delivered to cells using nuclear-
targeted mesoporous TiO2 NPs, achieving G2 cell cycle arrest in
the most radiosensitive G2 phase.[115]
In addition to water, molecular oxygen is a major partici-
pant in many reactions generating ROS from radiolytic prod-
ucts. Its concentration in cells and tissues is critical for the rela-
tive abundance of the various ROS generated by ionizing radia-
tion. Radiation-induced ROS generation in vivo is limited by tu-
mor hypoxia caused by inadequate blood supply. This has been
addressed clinically by approaches such as hyperbaric oxygen,
blood substitutes that carry oxygen, or hypoxic radiosensitizer
drugs such as misonidazole, metronidazole, and tirapazamine
that selectively kill hypoxic cells.[104,116] NPs have also been ex-
plored preclinically to improve radiosensitization as well as to
address tumor hypoxia, including hafnium oxide NPs (NBTXR3:
Nanobiotix, USA, currently in clinical trials) or gold and man-
ganese dioxide core–shell NPs with a polyethylene glycol (PEG)
coating.[117] For example, administering different formulation
of MnO2 NPs (hydrophilic terpolymer–protein–MnO2 and hy-
drophobic polymer–lipid–MnO2) in highly hypoxic murine or
human xenograft breast tumor models increased the radiother-
apy efficacy, reducing tumor growth and VGRF expression.[118]
In this work 40% of tumor-bearing mice became tumor free af-
ter a single treatment with a 2.5-fold lower radiation dose than
that required to achieve same outcome without NPs.
3.2. Cellular Antioxidant Response to ROS Generated by
Radiation
Cells are not in thermodynamic equilibrium with the environ-
ment due to internal energy generation, but rather support a
nonequilibrium steady redox state.[119] The overall cellular re-
dox state reflects the state of multiple individual redox couples
such as NAD+/NADH, some of which are linked.[120,121] Quanti-
tatively, the effective reduction potential (Eeff) of a redox system





where the index, i = 1, …n, denotes different redox couples and
ai =
CiZi∑n
j = 1 CjZj
(12)
is the specific charge transferred in a given reaction, Ei is the
reduction potential, ci is the molar concentration of reduced
species, and zi is the number of electrons which transfer to the
oxidized species of a given couple in one redox reaction.[120] Un-
der normal conditions the redox state is tightly regulated, with
intracellular ROS production is balanced by the antioxidant sys-
tem to maintain cellular homeostasis.
Antioxidants are reducing agents whose role is to neutralize
the ROS and free radicals generated as a result of respiration,
metabolism, cell signaling, and other processes and environmen-
tal exposure. These antioxidants include tocopherols and ascorbic
acid, carotenoids, and other flavonoids, and peptides such as glu-
tathione, the antioxidant enzymes include superoxide dismutase,
catalase and glutathione peroxidase, the thioredoxin system, and
free amino acids.[84,86] Glutathione is the most abundant cellu-
lar antioxidant, with concentrations of 1 × 10−3–11 × 10−3 m in
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the cytosol, 3 × 10−3–15 × 10−3 m in the nucleus and 5 × 10−3–
11 × 10−3 m in the mitochondria.[78] Due to its high abundance,
the reduction potential of the glutathione/glutathione disulphide
couple can be considered as a surrogate for the overall cellular
redox state.[119,121] Disturbing the cellular redox state by affecting
the balance between ROS production and elimination leads to ox-
idative stress. The exogenous formation of free radicals in cells
increases oxidative stress[60,121,122] and more than 60% of the cel-
lular damage caused by X-rays is due to this effect.[123]
ROS are endogenously generated in cells at multiple sites,
including mitochondria, endoplasmic reticulum, and lyso-
somes/peroxisomes in the course of metabolism and autophagy,
as well as in response to cytokines, xenobiotics, and microbial
invasion.[124] The molecules and processes mobilized by cells to
respond to ROS/RNS generated by radiation are the same as
those regulating the cellular antioxidant system,[125] for example,
upregulation of cyclooxygenases, nitric oxide synthases, lipoxy-
genases, and nicotinamide adenine dinucleotide phosphate oxi-
dase (NADPH oxidase), and the Nrf2 antioxidant response.[125,126]
This upregulation activates critical cytoprotective defences. These
regulatory mechanisms offer adequate protection at low ROS
doses/dose rates but become inefficient at higher doses/dose
rates.[86]
It is also noteworthy that cells exhibit natural variations in free-
radical responses, related to cell cycle or circadian cycles. Sig-
nificant differences in radiation sensitivity are observed in var-
ious phases of the cell cycle, being most resistant in late S phase
and most sensitive in mitotic G2/M phase: G2/M > G1 > early
S> late S.[127] Additionally, the expression levels of many ROS-
responsive genes or antioxidant enzymes are regulated by the
clock genes.[128]
Weakening the antioxidant response and/or blocking antiox-
idant synthesis can accelerate cell death, in a way that is can-
cer selective. This can be achieved with antioxidative enzyme
inhibitors, such as l-buthionine sulfoximine, a drug which in-
hibits glutamate-cysteine ligase that is the rate-limiting enzyme
in glutathione synthesis. Other drugs, including b-phenylethyl
isothiocyanate, zinc protoporphyrin, dimethylfumarate, and di-
ethylmaleate, deplete biologically-active GSH and amplify ROS-
induced oxidative stress.[104] By using this approach, ROS levels
can be modulated by tailored NP interventions. Recent work has
shown, for example, that GdVO4:Eu3
+ NPs increase ROS levels
in X-ray irradiated cells, whereas CeO2 NPs inhibit ROS genera-
tion under the same conditions.[129] Glutathione-depleting NPs
(histidine-coated gold nanoclusters) have been shown to sup-
press antioxidant cell responses to ROS,[130] offering an alterna-
tive way of amplifying oxidative stress. These NPs were able to
arrest a significant proportion of cells at the radiosensitive G2/M
phase, while in vivo studies confirmed tumor inhibition and fast
renal clearance of the NPs. Thus, antioxidant response suppres-
sion provides a new NP-based strategy to enhance cancer radio-
therapy.
3.3. Cellular Repair of Radiation-Induced DNA Damage
Cells engage dedicated mechanisms to restore the integrity of
damaged DNA. The SSBs are recognized by enzymes from the
poly (ADP-ribose) polymerase (PARP) family, such as PARP1,
and rectified by the base-excision repair machinery.[82] The
DNA damage response is additionally orchestrated by phos-
phatidylinositol 3-kinase (PI3K), mitogen-activated protein ki-
nase (MAPK), and SIRT pathways. Furthermore, DNA damage
signals activate cell cycle checkpoints and arrest cells in the G2/M
phase, to provide time for DNA repair systems to work.[131] The
ATM and ATR kinase signaling cascades are also initiated.[104]
The DNA repair can be hindered, for example, by using PARP
inhibitors[132,133] or by knocking down PARP expression with
siRNA, which may be delivered by using NPs.[134] Such block-
ing of DNA repair enhances the effectiveness of ROS generated
by limited radiation doses.
3.4. Cellular Pathways Affected by Radiation
The key mechanisms underlying cellular response to ionizing
radiation have been the focus of many studies and multiple
pathways have been found to contribute.[135–137] These involve
DNA repair machinery, controlling cell cycle checkpoints, cellu-
lar senescence, autophagy, apoptosis, cell metabolism, etc., each
linked to multiple cellular pathways. For example, DNA dam-
age activates the G1/S and G2/M cell cycle checkpoints to allow
more time for DNA repair,[133] so that tumors can be radiosensi-
tized by drugs that block the activation of the G2/M checkpoint.
Radiation affects the HIF-1 pathway, enhancing glycolysis and
also the pentose phosphate pathway, which increases the produc-
tion of antioxidants that buffer ROS.[104] Radiation-induced ROS
also affect the glucose transporter 1 (GLUT1) mechanism es-
sential for glucose metabolism. The AKT/mTOR/STAT3 signal-
ing pathway upregulated by radiation activates several epithelial-
mesenchymal transition transcription factors, including SNAI1,
HIF-1, ZEB1, and STAT3, thereby promoting cancer cell metas-
tasis. The proteins ATM, ATR, and downstream kinases, as
well as the proapoptotic proteins BAX and p53 may also be
upregulated. The Ras/MAPK/ERK and Ras/PI3K/AKT signal-
ing pathways involved in regulation of cell proliferation, sur-
vival, differentiation, and angiogenesis may also be affected by
radiation.[133,138] Cell adhesion molecules may be upregulated by
radiation which promotes cancer invasion. The expression of
tumor-suppressing miRNAs, such as miR-29c and miR-22, may
also be altered.[104,138] It is worth mentioning other in vivo re-
sponses to radiation, including alterations in tumor microenvi-
ronment such as extracellular matrix alterations, angiogenesis
a well as the immune response (Figure 4). Radiation-induced
DNA and membrane damage, as well as cytoplasmic ROS, acti-
vate many transcription factors and signaling pathways (includ-
ing mTOR, IGF, and CXCL8) that modulate the immunopheno-
type and immunogenicity of tumor cells.[139] Importantly, radia-
tion upregulates the expression of immune-checkpoint ligands,
including PD-L1, on the surface of tumor cells and on immune
cells in the tumor microenvironment. This, in turn enhances the
density of immune-cell infiltrates allowing the immune system
to fight the tumor.[139]
3.5. Other Cellular Responses to Radiation: Resistance
Mechanisms
Radiotherapy aims to prevent cell proliferation by inducing cel-
lular responses such as necrosis, apoptosis or senescence.[140–143]
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Figure 4. Combining radiation with agents that target the specific cellular pathways offers new tumor treatment strategies. ATR, ataxia telangiectasia
and Rad3-related protein; CA9, carbonic anhydrase 9; Chk1, checkpoint kinase 1; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; DDR, DNA
damage response; DNA-PK, DNA-dependent protein kinase; HIF-1-𝛼, hypoxia-inducible factor 1-alpha; MCT 1, monocarboxylate transporter 1; MCT 4,
monocarboxylate transporter 4; mTOR, mechanistic target of rapamycin; PARP, poly(ADP-ribose) polymerase; PD-1, programmed cell death protein
1; PI3K, phosphoinositide 3-kinase; NF-𝜅B, nuclear factor-kappa-B. Adapted with permission under the Creative Commons Attribution License.[164]
Copyright 2016, Springer Nature.
In apoptosis and necrosis, the damaged cells die, while senes-
cence arrests the cell cycle. If ROS exposure induces a sufficient
level of oxidative stress then no controlled pathway to cell death
can be followed, resulting in necrosis, characterized by rupture of
the cytoplasmic membrane, explosive release of cellular contents,
and massive inflammatory response in vivo. These responses
can be induced intentionally, for example, by using membrane-
targeted NPs that generate 1O2 induce necrosis by destroying
cell membranes.[144] Excessive levels of ROS have been linked to
apoptotic cell death, including death mediated by mitochondrial,
cell-death receptor and/or endoplasmic reticulum pathways.[145]
Cells can also undergo autophagy, a process by which they re-
absorb their own components, leading to self-destruction or sur-
vival, depending on the conditions.[133] Autophagy may be trig-
gered at more modest levels of ROS than required for necrosis. At
low-enough levels of radiation-generated ROS, cells can mount
transient responses, including DNA repair and antioxidant gen-
eration, resulting in proliferative survival.
As radiation is reliant on the generation of ROS, a hypoxic en-
vironment where unbound oxygen is scarce represents one of
the major components of resistance by which radiotherapy be-
comes ineffective. In hypoxia, the hypoxia-inducible transcrip-
tion factors (HIF), key regulators of the hypoxic response be-
come overexpressed via HIF prolyl hydroxylases (PHDs).[146,147]
These enzymes rely on oxygen for HIF degradation, thus, dur-
ing hypoxia, PHDs become inactive, and HIF may accumulate.
Alternatively, HIF activation is also mediated through signal-
ing mechanisms including the unfolded protein response and
mTOR signaling.[147] These independent pathways which are in-
tegrated with each other and within HIF activation ultimately
increase HIF signaling.[148] HIF modulates genes which aid in
adapting the cell to hypoxic conditions by reducing oxygen con-
sumption via shifting energy metabolism to the glycolytic path-
way which requires less oxygen than the alternative oxidative
phosphorylation pathway.[149] Additionally, HIF stimulates angio-
genesis which increases vascular flow to hypoxic tumor areas.[149]
The increase in glycolytic metabolism leads to the production of
lactate, which further acidifies the extracellular environment.[150]
The combination of acidification along with altered angiogenesis
created an environment in which low levels of oxygen are avail-
able for radiolytic ROS generation environment.[150]
3.6. Pharmacological Radiosensitizers
Pharmacological methods of radiosensitization by interfering
with cellular processes during and post radiation have been well
established, and many clinical radiosensitizers have been devel-
oped. Most commonly used clinical radiosensitizers include cis-
platin, 5-fluorouracil (5-FU), gemcitabine, and taxanes.[12,151,152]
Some radiosensitizers (e.g., nitroimidazole/intercalator conju-
gates, nitroquinoline intercalators) act by intercalating with the
DNA and destabilizing its structure so that it is more easily dam-
aged by X-rays.[12] Others directly interfere with specific cellular
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Table 2. Examples of clinically approved radiosensitizers.
Drug Mechanism of action Target pathway Radiation dose
enhance-ment factor
Conditions Ref.
CC2 Inhibits EGFR receptor to inhibit VEGF
production and tumor angiogenesis
EGFR 1.59–3.62 Normal [157]
Celotoxib Enhanced radiation-induced G2-M arrest COX-2 1.2–1.9 Normal [158]
Gemcitabine Causes S-phase arrest Chk1 1.3–1.8 Normal [159,160]
Olaparib (AZD2281) Delays DNA double strand break repair PARP1 1.4–2.5 Normal [161]
Pentoxifylline Inhibits G2/M block reducing time between
DNA repair and mitosis
PDE 1.3–6.0 Hypoxic [162]
Perifosine Enhances radiation-induced apoptosis Akt 1.3 Normal [163]
Vorinostat Inhibits NHEJ and HR DNA repair system and
abrogates EGFR and NF-𝜅B signaling
HDAC 1.4–1.6 Normal [153]
pathways, for example, enhanced apoptosis can be accomplished
by increasing the activity of specific (proapoptotic) genes or by
decreasing their activity using inhibitors. Alternatively, similar
interventions may be applied upstream or downstream of the
relevant cellular pathways. As an example, histone deacetylases
(HDACs) are required for DNA repair following radiation. Corre-
spondingly, the application of HDAC inhibitors such as Vorino-
stat increase DNA radiation damage.[153] Table 2 provides a list
of clinically approved radiosensitizers and their mechanisms-
of action-including their target pathways and also their radia-
tion sensitization factor. This factor also variably called “an SER”
or “radiation dose enhancement (DEF)” determines the ratio of
doses without and with radiosensitizers which have the same bi-
ological effectiveness. This term is conceptually simple but dif-
ficult to determine due to scarcity of coherent and systematic
experimental approaches to fully evaluate the radiobiological ef-
fectiveness of different agents[154] There seems to be consensus
that for most of the clinical sensitizers the SERs/DEFs are in the
range of 1.2 to 1.3 (a 20% to 30% increase in the effective dose
to the tumor[155] (noting that it is cancer and tissue-dependent).
Higher values are also reported in the literature for less fre-
quently used clinical preclinical radiosensitizers, as seen in Ta-
ble 2, e.g., 1.79 (79% increase) was reported.[156] Various (preclin-
ical) types of gold NPs reviewed by Her et al.[24] are reported to
have SERs/DEFs in the range of 1–3 (up to 200% increase).
The radioresistance pathways and mechanisms have been well
investigated and a large number of approved or candidate drugs
exist that interfere with key components of these pathways (Fig-
ure 4, see also ref. [73]). We listed in Table 2 some example ra-
diosensitizer drugs as many of them may be well-suited to com-
bining with the nanomaterial optimization strategies discussed
below. Thereby, the cellular ROS response can be manipulated to
increase vulnerability of cancer cells, maximize tumor ablation
and increase the effectiveness of the radiation dose.
4. Interaction of Radiation with Nanoparticles:
Physical and Chemical Effects
We now summarize the interaction mechanisms of radiation
with NPs that may be utilized to maximize the ROS generation
rates.
4.1. Dose Partitioning
Dose partitioning is the primary effect that may occur in and
around NPs located within tissue when they interact with ion-
izing radiation. This effect is driven by the difference in atomic
mass in NPs, compared with the average atomic number in
cells/tissues of ≈3–7, and it is most pronounced for high Z
(atomic number) NPs. In dose partitioning, an increased fraction
of the X-ray photon energy is deposited close to NPs such as gold
(Z = 79), as a result of increased photoelectric interactions,[165]
thereby enhancing the local radiation dose.[166–170] Monte Carlo
simulations have established that combining a typical radiation
treatment with Au NPs for ≈100 keV X-rays and 0.2–0.6 MeV 𝛾-
rays from 192Ir results in a >10% dose enhancement for achiev-
able gold concentration of 7 mg Au per gram in tumors,[165] al-
though the dose enhancement at typical radiotherapy energies
of > ≈4–6 MeV is not highly pronounced. Radiation dose en-
hancement has been reported also for other metal-containing
NPs, including platinum,[171] iridium,[172] selenium[173] Fe–Pt
clusters,[174] superparamagnetic iron oxide,[175] as well as gadolin-
ium MRI-contrast agents,[176] as reviewed by Liu et al.[177] In addi-
tion to the effect of high Z, NP aggregation is able to produce hot
spots of dose enhancement.[178] The dose enhancement is LET-
dependent, being higher at low X-ray energies,[179,180] such LET-
dependent radiosensitization with Au NPs has been reported by
Li et al.[181]
4.2. ROS Generation at Nanoparticle Surfaces by Light or
Ionizing Radiation
The second important effect is ROS generation at the NP sur-
face. For example, light excitation of inorganic NPs such as TiO2,
ZnO or Si at photon energies above the bandgaps of 3.2 eV (TiO2),
3.36 eV (ZnO), and 1.4 eV (Si) produces electron/hole pairs that
induce a series of ROS-generating reactions in the aqueous com-
ponent. For example, small (<5 nm) Si NPs generate 10 × 10−6
m of ROS (O−2 /HO
∙
2, HO
•, and H2O2) per Gy in a 6.4 × 10−6
m aqueous solution of Si NPs under 4 MeV X-ray radiation,[182]
which translates to 2.5 × 108 ROS per Gy in a sphere of 10 µm ra-
dius, comparable in size to a cell. Assuming a typical clinical dose
rate of 200 cGy min−1,[183] the generation rate is 8 × 105 ROS per
second per cell, compared to the basal metabolic rate of ≈105.[82]
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Figure 5. a) Interactions of X-rays with NPs in aqueous solution (note that some of these reactions require dissolved oxygen). Reproduced with
permission.[184] Copyright 2011, Elsevier. b) Hydroxyl and hydrated electron yields produced by Au NPs during radiotherapy and the corresponding
ROS enhancement factor. Reproduced with permission.[99] Copyright 2018, Elsevier.
The yields of specific radiolysis products at solid/liquid inter-
faces can be significantly higher than in bulk water,[57] so that
the ROS generated by a given radiation dose can be distinctly
higher in the presence of NPs than without.[99,184] For example,
Cho quantified this enhancement for different Au NP concentra-
tions (7, 18, and 30 mg/1 g of tissue) by Monte Carlo calculations
for 140 kVp, 4 and 6 MV photon beams, and 192Ir gamma.[165] The
average dose enhancement over the tumor volume in this work
was 2.0 and 5.6 in the presence of 7 mg /1 g and 30 mg /1 g of
Au inside the tumor for 140 kVp X-rays. The dose enhancement
was much lower in the case of 4 MV X-rays (1.009 and 1.032 for
7 mg/1 g and 30 mg/1 g of Au) and 6 MV X-rays (1.007 and 1.025
for 7 mg/1 g and 30 mg/1 g of Au). These data provide a clear in-
dication that clinically significant tumor dose enhancement can
only be achieved with low energy X-ray photons.
There are several possible mechanisms for ROS generation
in NPs. One example[99] is illustrated in Figure 5a where we
highlight the secondary electrons with energies higher than the
work function of the material (5.2 eV for Au).[184] These elec-
trons are then released from the NP to the solution, where sub-
sequent reactions produce ROS. An alternative mechanism pro-
ceeds through generation of excited electron–hole pairs in the
NPs (Figure 5a). The pairs that do not rapidly recombine pro-
vide electrons and holes that individually may escape the NP and
undergo redox reactions in the solution.[100] Finally, an excitonic
effect may take also place,[185] where the energy of the bound-
electron hole pair (exciton) is transferred out from the NP to the
solution where it facilitates ROS generation (Figure 5a). The net
effect of these processes is generation of ROS that is over and
above the amounts generated by radiation in the absence of NPs
(Figure 5b). The opposite effect, namely ROS scavenging by NPs,
has also been shown. For example, CeO2 NPs are efficient scav-
engers of ROS such as HO• and RNS such as NO•.[186]
4.2.1. Similarities between Photocatalysis and Radiocatalysis
Having established that ionizing radiation interacts with many
types of NPs to generate ROS,[187] we now consider how to in-
crease ROS generation from the available radiation dose. One
approach is to draw analogies between photocatalysis and radio-
catalysis in the presence of solid surfaces that may lower the ac-
tivation energies. Although the initial physical effects are differ-
ent, they lead to the same outcome, with the energy of light or
radiation dispersed into heat and, under specific conditions, elec-
tron emission, and excitation of electron–hole pairs. As a result
of this similarity, many aspects of radiocatalysis and photocatal-
ysis are qualitatively similar, allowing insights from photocatal-
ysis to explain radiation-induced processes. For example, TiO2
NPs are excellent photocatalysts for ROS generation, particularly
when coated with Au, Ag or Pt,[188–190] suggesting that TiO2 NPs
may be effective radiosensitizers, as reported.[191] Excitation of
inorganic NPs such as TiO2, ZnO or Si at photon energies ex-
ceeding their bandgaps of 3.2, 3.36, and 1.4 eV, respectively pro-
duces electron/hole pairs that induce a series of chemical reac-
tions in aqueous solution to generate ROS.[192] It could, there-
fore, be expected that both pure ZnO and SiO2-coated ZnO NPs
would serve as sensitizers in radiation-induced PDT. Indeed, it
has been demonstrated that the cell kills by such NPs in human
prostate adenocarcinoma cell lines was increased by a factor of
1.5–2 compared to radiation alone.[193]
ROS generation under X-ray exposure may also be partly at-
tributed to CR light-induced PDT, although this is limited by
the number of light photons generated at clinical X-ray doses.[70]
CR-mediated PDT has been reported,[194–199] for example, with
TiO2 NPs,
[198,200] in conjunction with radiolabeled 2′-deoxy-2′-
(18F) fluoro-d-glucose (FDG) (half-life: 1.83 h, 𝛽+: 0.633 MeV,
97%) and 64Cu (half-life: 12.7 h, 𝛽+: 0.653 MeV, 19%, 𝛽−: 0.579
MeV, 39%) used to generate CR. In this work, FDG was pref-
erentially metabolized by tumors (human fibrosarcoma, HT
1080), allowing tumor-specific targeting and CR generation. The
NPs were conjugated with apo-transferrin (Tf) for tumor tar-
geting, while additional conjugation of titanocene (Tc), a pho-
toinitiator in the metallocene family, enhanced and comple-
mented the cytotoxicity of TiO2 (Figure 6a–g). A significant
shrinkage of the tumor volume (40%± 5% within three days)
and a complete tumor regression by 30 days was achieved in
this work. This result indicates that CR mediated ROS genera-
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Figure 6. a) Schematic of CR-mediated ROS generation from TiO2 NPs. b) Schematic of TiO2–PEG, TiO2–Tf, and TiO2–Tf–Tc synthesis. c) HT1080
tumor growth in mice using the NPs and 64Cu, together with controls. b) Reduction in tumor size at 1, 3, and 45 d post treatment (single dose of 2.5 µg
mL−1 TiO2–PEG and 0.5 mCi/0.1 mL of
64Cu). e) Tumor growth following a single intratumoral administration of TiO2–Tf–Tc with FDG radionucleotide,
together with controls. f) FDG-PET imaging of untreated (left) and treated (right) mice with bilateral HT1080 tumors at 15 and 30 d, respectively. g)
H&E stained treated and control tumor sections at two different magnifications (T-tumor, N-necrotic *-denuded areas indicating macrophage-assisted
tumor cell clearance). Reproduced with permission.[198] Copyright 2015, Springer Nature.
tion may be sufficient for an effective treatment of deep-seated
tumors.
4.2.2. Charge Transfer Photo- and Radiocatalysis-Redox Reactions
Solid surfaces in an aqueous environment may catalyze light-
and radiation-induced ROS-generating redox reactions,[100,201,202]
hence understanding the photocatalytic redox reactions aids in
optimizing ROS yields in generally less-well explored radiocatal-
ysis. ROS may be created from both H2O and any available O2 by
consecutive reactions. HO•, H2O2, O
−
2 , and
1O2 are generated by
stepwise oxidation of H2O, while stepwise reduction of O2 gen-
erates O−2 , H2O2, and HO
•, (Figure 7), as for example detailed by
Nosaka and Nosaka.[100]
The basic mechanism of light- or radiation-mediated redox re-
actions is illustrated in Figure 8a, where an absolute potential of
the standard hydrogen electrode of−4.42 eV[203] was used to align
the conduction and valence band edges with the values of the
redox potential. Most of the excited (thermalized) electrons and
holes rapidly recombine (90% within 10 ns in TiO2
[204]) but some
can tunnel out of the solid to participate in redox reactions in the
water at the NP surface. For the reduction reaction to occur, the
conduction-band edge of the solid surface must be located above,
i.e., be more negative than, the potential of the (oxidized) acceptor
species to make it energetically favorable for the excited electron
to migrate out of the solid. Likewise, when the valence band edge
of the solid surface is below, i.e., more positive than, the potential
of the donor (reduced) species, then it is energetically favorable
for the photoexcited hole to migrate out of the NP.[202] Charge
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Figure 7. Reactive oxygen species generated in photocatalysis at the
NP surface in oxygenated aqueous environment. Reproduced with
permission.[100] Copyright 2017, American Chemical Society.
neutrality must be maintained in this process, so that for each
charge vacating the solid the opposite charge must leave the solid.
This process may be facilitated by electron/hole scavenger com-
pounds such as ascorbic acid conjugated to or adsorbed at the NP
surface.[205,206] If such scavengers are not provided, then the NPs
undergo chemical degradation or, for example, may chemically
transform the adsorbed ligands, leading to NP aggregation.[205]
Close alignment of the conduction band and/or valence band
edges with the reduction and/or oxidation potentials is desirable
for efficient reduction and/or oxidation.[202,207] It should be noted,
however, that these considerations do not impact the reaction
rates, which are determined by activation energies and concen-
trations.
As an example, TiO2 in aqueous suspension generates ROS
upon irradiation with light of sufficient energy (>3.2 eV) to
produce electron–hole pairs.[204] These electrons and holes are
able, respectively, to take part in reduction and oxidation reac-
tions, with redox potentials shown in Figure 8a. These potentials
are strongly influenced by the presence of the TiO2 surface
[207]
and depend on the solution pH, as described by the Nernst
equation.[121,208] The ROS photoproducts on the TiO2 surface are
reported to be O−2 , HO
• radicals, and H2O2, created in the follow-
ing reactions[204]
O2 + e− → O−2 (13)
The HO• generation can be increased by adding H2O2 to the
NP solution, according to
H2O2 + e− → HO∙ + OH− (14)
H2O2 + O−2 → HO
∙ + OH− + O2 (15)
The hydroxyl ions are also generated from water but at low
yield. This process involves the oxidation of OH−(H2O) by pho-
togenerated holes in the valence band (h+vb )
h+vb + OH
− → HO∙ (16)
h+vb + H2O → HO
∙ + H+aq (17)
It is also worth noting that electron acceptors (such as com-
pounds containing, e.g., Fe3+) are capable of stimulating HO•
generation, as they may inhibit electron–hole recombination in
the solid and thus facilitate the interaction of holes with water.[204]
Such electron acceptors can be incorporated as part of the NP de-
sign.
4.2.3. Heterojunctions and Carrier Storage in Charge Transfer Photo-
and Radiocatalysis
The photo- and radiocatalytic properties of NPs may be opti-
mized to ensure high ROS yields by reducing the probability of
recombination of the excited electron–hole pairs. A heterojunc-
tion approach ensures that these charge carriers can be more
effectively utilized in redox reactions with charge transfer out
of the NPs. For example, trapping electrons in a semiconductor
NP combined with a metal such as Au has been used to induce
charge separation.[209] Photocatalytic semiconductor NPs based
on the application of heterojunctions for enhanced ROS gener-
ation have been also proposed[202] and photocatalytic NPs based
on bismuth oxyiodide (BiOI) have been explored as a radiosensi-
tizer in X-ray excited PDT, where the radiosensitization was en-
hanced by coating the BiOI surface with Bi2S3 to form hetero-
junction NPs with low electron–hole pair recombination energy
(Figure 8b). This work used a “sandwich” geometry so that both
sides of the NP-embedded heterojunctions are exposed to water,
enabling opposite migration of electrons and holes. An alterna-
tive strategy, implemented[210] is to ensure that one type of charge
is captured in the material, allowing the opposite charge to take
part in the redox reactions unhindered by the Coulomb attrac-
tion to its counterpart. An important prerequisite for this is long
electron–hole pair lifetime, so that it is beneficial to reduce the
electron–hole recombination rate, for example, by facilitating the
formation of triplet exciton states.[205]
4.2.4. Resonant Effects in Energy-Transfer Photocatalysis
The modification of ROS yields in redox reactions discussed
above suggests a range of potential optimization strategies, al-
though none provide high amplification. However, resonance
phenomena uncovered in research on photocatalytic water
splitting[185] promise a much higher enhancement. For example,
an ≈100-fold increase in hydrogen yield was reported on solid
surfaces with a bandgap ≈5 eV that is close to (resonant with) the
energy of the H–OH bond in water (5.1 eV) (Figure 9a),[185] which
was attributed to energy transfer from excitons to the H–OH
bond,[211] a mechanism referred to as “energy transfer photocatal-
ysis,” as reviewed by Strieth-Kalthoff et al.[212]
In general, energy transfer is a photochemical process where
a donor molecular entity in an excited state (D*) is deactivated to
a lower state (D) by transferring its energy to an acceptor (A) to
produce the excited state (A*)
D∗ + A → D + A∗ (18)
This is distinct from charge-transfer photocatalysis that in-
volves redox processes, where charges rather than energy are
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Figure 8. a) Energy level diagram for the steps in water oxidation: red – electronic, blue – protonic. Solid lines represent levels calculated on TiO2; dashed
lines are experimental levels in aqueous solution. Black arrows – dehydrogenation potentials, dotted black line – standard redox potential of the overall
water oxidation reaction. Reproduced with permission.[207] Copyright 2014, Wiley-VCH. b) Mechanism by which BSA-coated BiOI@Bi2S3 semiconductor
heterojunction NPs enhance the efficiency of ROS generation by ionizing radiation. Reproduced with permission.[202] Copyright 2017, Wiley-VCH.
Figure 9. a) Yields of molecular hydrogen as a function of oxide bandgap in radiolysis of water adsorbed on various oxides. Reproduced with
permission.[185] Copyright 2001, American Chemical Society. b) Charge transfer photocatalysis involving redox processes.
transferred (Figure 9b). Energy transfer is mediated by Coulomb
dipole–dipole and exchange interactions and it typically does not
involve photon transfer, so that A does not need to have apprecia-
ble optical absorption for this process to be effective. Generation
of singlet oxygen in PDT is an example of energy-transfer pho-
tocatalysis. The energy transfer is facilitated if D* is long-lived
(>100 ns), as in triplet molecular states. Strong excitonic effects
lead to low yields of free charge carriers and limit the mobility
of charge carriers, which increases the quantum yield of energy-
transfer photocatalysis.[211]
Energy-transfer often exhibits resonant behavior, as seen for
example in plasmonic resonances.[213–215] The energy transfer
photocatalysis mechanism is relevant for ROS generation, for
example, in the novel material, 2D black phosphorus,[211] where
the close valence band edge and redox potential enables effective
water oxidation and the formation of hydroxyl ions. Excitonic ef-
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fects in energy-transfer photocatalysis have been demonstrated to
increase photocatalytic yields.[210] For example, the closeness of
the excitonic-state energy and the 1O2 conversion energy enables
effective generation of 1O2.
[216] The presence of excitonic reso-
nances in photocatalysis suggests the possibility of resonantly en-
hanced ROS yield in radio-catalysis as well, and we propose that
this could be achieved by carefully tuning NP systems through
bandgap engineering, doping or the application of novel low-
dimensional materials.
4.2.5. Effects of Surface Functionalization and Coatings on ROS
Generation
NP surface properties such as interfacial layers, coatings, func-
tionalization, and/or capping agents can play a significant role in
ROS generation.[217,218] They can mediate chemical reactions, for
example, in processes where electrons and/or holes generated in
the NPs interact with the ligands before they are released into
solution and take part in ROS-generating redox reactions. These
intermediate steps may change the ROS yields and kinetics as,
for example, in adsorption of O2 at the surface of AuNPs, which
disrupts water organization at the NP surface and reduces the
radical production rates.[99]
The surface charge of NPs solids, as reflected by their zeta po-
tential, ensures their colloidal stability by changing the energy-
level structure of the solid–liquid system, since the Coulomb en-
ergy from the additional charge combines with the electronic
energy to increase the total electron energy. The surface charge
density also produces band bending (Figure 10a,b) and leads to
the organization of ions and coions in solution according to the
Gouy–Chapman–Stern theory.[219] The interfacial water layer it-
self is also organized.[99] The presence of charged adsorbates at
the solid–liquid interface additionally modifies the arrangement
of surface charges and leads to the potential profiles illustrated
in Figure 10a,b, as a result of which the aligned vacuum levels
undergo spatial modification near the interface. Other signifi-
cant energy levels, such as conduction and valence band edges
as well as redox potentials, follow the spatial variations of elec-
trical potential according to the energy addition principle, and
lead to alterations of the energy required for electrons to take part
in redox reactions (Figure 10c–f). This energy varies from nega-
tive (Figure 10d) to positive (Figure 10f) as a result of changes in
the surface charge density and polarity. The former can be easily
engineered by modifying the NP coating/functionalization,[220]
which offers a potentially simple way to improve the alignment
of conduction and valence band edges with the redox potentials in
water. Thus, surface phenomena such as the surface charge, in-
terfacial organization of molecular species, and capping and/or
functionalization can be exploited to optimize ROS generation.
The published literature provides numerous examples that the
surface chemistry of NPs, and properties such as surface charge
are able to affect the amount of ROS generated by NPs.[221,222]
For example, positively charged Si NP-NH2 proved to be more
cytotoxic in terms of reducing mitochondrial metabolic activity
and effects on phagocytosis than neutral Si NP-N3 because pos-
itively charged Si NP-NH2 were found to produce the highest
level of intracellular ROS.[223] Iron oxide NPs coated with posi-
tively charged chitosan were reported to produce abundant ROS,
underpinning their significant antimicrobial activity against Es-
cherichia coli and Bacillus subtilis.[224] High surface charge on car-
bon nanotubes has been found responsible for the prooxidant
effects of CNT.[225] It was also observed that increasing the hy-
drophobicity of the AuNPs increased their cytotoxicity, and in-
creased ROS production.[226] Similar effects have been reported
for the generation of hydroxyl radicals during radiolysis of wa-
ter in the presence of AuNPs.[99] Another example of the effect
of NP surface coating on ROS generation is decreased emis-
sion rate of electrons from PEG-coated AuNPs with increasing
PEG layer thickness, as well as altered secondary electron energy
spectrum,[205] both of which impact the ROS yield.
4.2.6. Effects of Nanoparticle Size and Shape on ROS Generation
The effects of NP size and shape on ROS generation upon ra-
diation exposure have been widely observed.[101] They also offer
scope for tuning the ROS yields. For example, the ROS genera-
tion rates are higher in smaller NPs due to the larger surface area
to mass ratio, combined with a linear dependence of the ROS
generation rate on the surface area, as reported for example for
AuNPs.[184] Other authors have also suggested a more efficient
electron emission from smaller NPs, since the excited electrons
have a lower probability of dissipating their energy inside the NP
before reaching the surface.[227]
The effects of NP shape on ROS generation, also widely
observed,[228] and they can be attributed to a different mix of crys-
talline orientations with varying chemical activity. The effect of
this orientation on the emission of electrons and reactive species
generation is well established, for example, in water splitting by
atanase and rutile TiO2 NPs whose crystalline surface ordering
differ.[229] Different orientations of nanocrystal facets yield suffi-
ciently variable chemical properties that fully anisotropic facet-
dependent functionalization has been realized.[230] Tuning the
NP shape offers a viable strategy to optimize ROS yields, espe-
cially if theoretical estimates of favorable surface energetics are
available.
4.3. Generation of Light from Scintillating Nanoparticles Exposed
to Ionizing Radiation
Scintillation refers to generation of light from materials exposed
to ionizing radiation.[231–234] In solid materials, this begins with
the creation of excited electron–hole pairs which migrate through
the material with some energy loss[235] or become trapped at spe-
cific defect centers where their radiative recombination generates
light.[231] Many materials, mostly organic and inorganic solids,
have scintillation properties. Inorganic scintillators such as CeF3,
YAG, BGO, LaCl3(Ce), LaBr3(Ce) are perhaps the best known and
are employed in radiation detectors.[232,236] NPs from these ma-
terials can be readily prepared. Scintillating NPs (SNPs) are able
to act as energy transducers for ionizing radiation and this can
be exploited for X-ray induced generation of ROS from conju-
gated PSs.[32,38,180,237–241] Many SNPs emit light in the UV–vis re-
gion in response to ionizing radiation[180,238] and can perform as
nanoscale light sources within the tissue, where they generate cy-
totoxic ROS.[37] Kamkaew et al. [32] provide an excellent review of
this topic.
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Figure 10. Effect of surface adsorbate on redox energy for a reaction where an electron leaves the solid surface to form a radical species. a,b) Ionic
and electric potential in the vicinity of a solid surface in the modified Stern model for (a) negatively charged surface and positively charged adsorbate
(negative zeta potential) and b) positively charged surface and negatively charged adsorbate (positive zeta potential). c–f) Conduction band edge and
redox potential in the presence of surface charges in solid charged adsorbate molecules and solution ions. The yellow arrow indicates the redox potential
value (identical in panels c–f). Arrows labeled ∆E indicate positive (red) or negative (green) energies required for the electron (black dot) to take part
in the redox reaction as marked. (The possibility of electron transfer to the adsorbate has not been noted here.) Note that the values of ∆E vary from
positive to negative depending on the surface concentration of adsorbate and its charge. The vertical axis reflects the distance from the solid surface;
distances are not to scale—the band bending in solids occurs on a µm scale, while the width of the adsorbate and distance from solid surface to the
slip plane are within nm. The electron is assumed to be located at the solid surface, reflecting its location in an NP. Valence and other band edges in the
solid have been omitted for clarity. (a,b) Adapted with permission.[220] Copyright 2012, Wiley-VCH.
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4.4. Free Radical Scavenging by Nanoparticles
While this review centers on enhancing radiotherapy with en-
gineered nanomaterials increasing the oxidative stress at the
therapy site, it is worth mentioning that mitigation of this
stress in adjacent healthy tissue also has a significant clini-
cal value—despite the well-developed technique of radiotherapy
planning. The application of NPs for radioprotection has been
discussed in[242,243] where key classes of nanomaterial radiopro-
tectors are listed. These include encapsulated molecular radio-
protectors such as flavonoids[244] or other compounds formulated
in liposomes,[245] polysaccharides,[246] fullerenes, carbon NPs of
various types[247,248] some of which are clinically approved as well
as inorganic ceria (CeO2).
[249] The latter represents a catalytic sys-
tem with interesting enzyme-mimetic properties able to reduce
oxidative and also nitrosative stress[186] mostly related to the of
the Ce3+/Ce4+ valence ratio on the NP surface. This area mer-
its further investigation as ceria under certain conditions was
found to differentially protect normal cells without affecting can-
cer cells.[250–252] However, under alternative surface conditions ce-
ria was found to enhance the effects of radiation.[253,254]
In order to fully realize the therapeutic benefit of protecting
healthy tissue unduly exposed to radiation the free-radical scav-
enging nanomaterials would need to be targeted to this healthy
tissue which represents a major problem. Targeting whole organs
would be an important, but extremely challenging first step. Pref-
erential renal or hepatic uptake has been demonstrated[255,256] fa-
cilitated by special physiology of these two organs. Organ-specific
drug delivery has been reviewed,[257] and it remains an active area
of research.
5. Interaction of Radiation with Photosensitizers:
Physical and Chemical Mechanisms
NP designs used in X-PDT may incorporate molecular PSs.
These generate additional free radicals (e.g., 1O2) beyond the
levels produced by water radiolysis. Many common dyes, in-
cluding methylene blue, crystal violet, phthalocyanine, and hep-
tamethine, are efficient PSs.[32,258] Some PSs, such as riboflavin
or porphyrins, are endogenous to cells.[259,260] Clinically ap-
proved exogenous PSs include tetrapyrrole structured hemato-
porphyrin derivative (HpD), Photofrin,[261–263] 5-Aminolevulinic
Acid (5-ALA) that leads to exogenous production of protopor-
phyrin IX (PpIX),[264] verteporfin (and its liposomal clinical for-
mulation, Visudyne)[239,265] and palladium bacteriopherophor-
bide, TOOKAD.[266,267] A range of other PSs including zinc ph-
thalocyanine, aluminum phthalocyanine tetrasulfonate, and lu-
texaphyrin are currently undergoing clinical trials.[268–270] Re-
cently discovered PSs based on aggregation-induced emission
(AIE) molecules offer enhanced 1O2 yields.
[271] For example, 80%
yield was reported for an oligo-ethyleneimine (OEI)-crosslinked
polycation, compared to 28% for the clinical Photofrin[272]). This
effect is due to restricted nonradiative decay channels in the
AIE systems.[273] Conversely, PSs activated by near-infrared light
(which is advantageous due to increased penetration depth in tis-
sue) have reduced yields of cytotoxic species due to their compar-
atively high nonradiative transition rates.[32] Additionally, both ex-
ogenous, but also endogenous PSs in cells (e.g., riboflavin) ex-
posed to light or to ionizing radiation may, in principle, be able
to change the balance of cellular ROS. It is, therefore, important
to understand the underlying molecular processes.
5.1. Interaction of Visible Radiation with Photosensitizers
Singlet oxygen generation by a PS is initiated by its excitation
with a photon of light that is spectrally matched to the absorption
by relevant energy levels in this molecule. The resulting excited
singlet state (PSE) may then undergo intersystem crossing to an
excited triplet state (PST), which has a comparatively long lifetime
(10−9–10−6 s).[274] The triplet state may then return to the ground
state (PSG) by initiating a photochemical reaction, leading to the
generation of ROS[275–277] through type I and/or type II reactions.
In type I reactions, the electron transfer from PST to the sur-
rounding biomolecules (substrate) generates free radicals that re-
act with available oxygen producing superoxide radical anions.
Further addition of a proton can lead to the formation of hydro-
gen peroxide (H2O2) or biologically reactive hydroxyl radicals.
[278]
Alternatively, in type II reactions, PST can transfer energy directly
to ground-state molecular oxygen (3O2) to generate
1O2.
[276,279]
Figure 11 illustrates these reaction pathways and types of ROS
generated. Type I and type II reactions can occur simultaneously,
their relative contributions depending on the oxygen concentra-
tion and the interacting biomolecules. The effectiveness of ROS
and 1O2 generation critically depends on the availability of molec-
ular oxygen.[280,281]
Singlet oxygen generation by a PS is initiated by its excitation
with a photon of light that is spectrally matched to the absorption
by relevant energy levels in this molecule. The resulting excited
singlet state (PSE) may then undergo intersystem crossing to an
excited triplet state (PST), which has a comparatively long lifetime
(10−9–10−6 s).[271] The triplet state may then return to the ground
state (PSG) by initiating a photochemical reaction, leading to the
generation of ROS[272–274] through type I and/or type II reactions.
In type I reactions, the electron transfer from PST to the sur-
rounding biomolecules (substrate) generates free radicals that re-
act with available oxygen producing superoxide radical anions.
Further addition of a proton can lead to the formation of hydro-
gen peroxide (H2O2) or biologically reactive hydroxyl radicals.
[275]
Alternatively, in type II reactions, PST can transfer energy directly
to ground-state molecular oxygen (3O2) to generate
1O2.
[273,276]
Figure 11 illustrates these reaction pathways and types of ROS
generated. Type I and type II reactions can occur simultaneously,
their relative contributions depending on the oxygen concentra-
tion and the interacting biomolecules. The effectiveness of ROS
and 1O2 generation critically depends on the availability of molec-
ular oxygen.[277,278]
5.2. Interaction of X-Rays with Photosensitizers
PSs have been shown to generate ROS upon exposure to X-
rays, in particular porphyrin-based molecules such as HpDs,
Verteporfin, protoporphyrin IX, and Photofrin II.[282,283] The
mechanisms have not been fully established, but several puta-
tive explanations have been put forward. For example, the initial
excitation to the singlet state PSE may be possible simply by in-
teraction of the PS molecule with radiation-induced secondary
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Figure 11. Jablonski diagram showing the possible events after a PS molecule has been excited. Type I reaction occurs as a result of charge transfer and
it may lead to the production of superoxide anion, hydrogen peroxide, and hydroxyl radicals, whereas the Type II reaction produces singlet oxygen via
energy transfer to ground-state oxygen. PSG – ground state PS; PST-triplet state PS, and PS−-reduced state PS. Adapted with permission.[96] Copyright
2016, Elsevier.
electrons[284,285] that generate molecular excitations, in a process
analogous to cathodoluminescence.[286] It is also worth mention-
ing that high energy X-rays beyond the Cherenkov energy thresh-
old can produce Cherenkov photons (CL). These, in turn, can ex-
cite the PS and generate highly reactive 1O2 via the conventional
photodynamic pathways as in Figure 11.
6. Example Nanoparticle Designs for X-PDT
The advancement of nanotechnology in the medical field opens
a range of possibilities to improve therapeutic efficiency, espe-
cially by combining multiple approaches such as radiation and
photosensitization for cancer treatments.[287] The mechanism of
ROS generation from NPs and PSs under light and X-ray radia-
tion and the active role played by the NPs may vary. The NPs can
either act as a scintillator to produce UV–vis light to activate the
PS, or act as a radiosensitizer or as a carrier for a radiosensitiz-
ing drug. In addition, the EPR effect and targeting possibilities
further improve the efficiency of NP formulated therapeutics. In
this section, we will consider the different roles of NPs in the con-
text of X-PDT and their therapeutic potential, particularly to treat
deep-seated tumors.
6.1. Scintillating Inorganic Nanoparticles Combined with
Photosensitizers
When scintillation NPs are integrated with PSs, the ROS gener-
ated upon X-ray exposure either directly by excitation of the PS,
or indirectly via the scintillation light from the NPs or via the CL
generated in the tissue. This raises the question whether combin-
ing PSs with NPs (either scintillating or not) leads to additional
ROS generation from a given radiation dose. This question is not
yet fully answered, but a theoretical study based on Monte Carlo
simulation shed some light in the efficiency of ROS generation
from scintillating NPs and PS which depends on several param-
eters, including the distance between the SNP and PS, the X-ray
photon energy, and the concentration and size of the NP.[288] This
was illustrated in the case of Gd2O3 NPs where the total energy
deposited in Gd2O3 NP and water following an interaction with a
specific energy X-ray photon was found to be different for differ-
ent occupation ratios (NP/tissue volume ratio). For example, the
interaction of 500 keV X-rays with 10 nm Gd2O3 NP in a tumor
at an occupation ratio of 2 × 10−3 deposits 1.1 keV of energy in
Gd2O3 NP, and 173.5 keV in water, respectively. At a higher occu-
pation ratio of 7 × 10-3, the deposited energy in NP was 3.71 keV.
However, when the NP size was increased to 100 nm at the same
occupation ratio of 7 × 10-3, the deposited energy was estimated
4.28 keV. These findings highlight the fact that a significant frac-
tion of energy is deposited within the NPs despite the primary
interaction occurring in the surrounding media and this influ-
ences ROS (in this case 1O2) generation.
[288]
A detailed quantitative analysis of the effectiveness of conjugat-
ing PSs to scintillating NPs is provided by Clement et al.[180] This
work centers on scintillating CeF3 NP that produce UV light upon
X-ray excitation to activate verteporfin (VP) to produce 1O2. In
this work, 60 Gy X-ray generated 1.2 × 108–2 × 109 1O2 molecules
per cell when the tissue contained a 5% volume fraction of CeF3-
VP conjugate. This is comparable to 1O2 concentration (≈5 ×
107 molecules per cell) that results in 1/e clonogenic surviving
fraction.[289]
Other scintillating NPs that have been used in X-ray activated
ROS generation include LaF3:Ce, ZnS:Cu, Co, Y2O3, Gd2O2S:Tb,
and LiGa5O8:Cr.
[27,239,290–293] For example, LaF3:Ce
3+, an effi-
cient scintillator with a strong emission peak at 520 nm has
been reported to excite a PS, PpIX[292] enabling the generation
of cytotoxic ROS under X-ray excitation. Recently, scintillating
LiGa5O8:Cr NPs together with the PS 2,3-naphthalocyanine (NC)
loaded into mesoporous silica NPs (NC-LGO:Cr@mSiO2) was
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Figure 12. a) Synthetic route for monodispersed SZNPs and the mechanism of radiation induced PDT. b) Emission spectra of SCNPs, SCNP@SiO2
NPs under X-ray excitation, UV–vis absorption spectra of SZNPs. The inset shows the energy-level diagram of Ce3+ in LiYF4 crystal. c) ROS production
as function of radiation dose indicated by change in MB absorption (𝜆 = 664 nm) for SZNP and control solutions. d) H&E staining of tumor at 48 h
after treatment with SZNP under 8 Gy radiation dose. Reproduced with permission.[297] Copyright 2015, Wiley-VCH.
also used for X-PDT.[293] Interestingly, the X-ray excited lumines-
cence from LiGa5O8:Cr is persistent, lasting for hours after radia-
tion has ceased, and its spectrum falls into the far-red wavelength
range (≈720 nm). The tumor-specific antibody Cetuximab was
conjugated to the carboxylic group on the surface of these NPs
and the in vivo treatment in an H1299 orthotopic tumor model
in mice with 6 Gy X-ray dose showed strong growth suppres-
sion compared to untreated controls. Another study also reported
tumor responses using a scintillating copper–cysteamine NP
complex (Cu–Cy) activated by X-rays.[294,295] Interestingly, these
NPs also produce 1O2 in the presence of microwave radiation,
which may represent an alternative approach to treat deep-seated
tumors.[296]
A further example of a more complex inorganic nanostruc-
ture is SCNP@SiO2@ZnO-PEG (SZNP) which brings together
a nanoscintillator (LiYF4:Ce
3+) coated with SiO2 (SCNP@SiO2)
and a semiconductor NP (ZnO), with PEGylation for enhanced
biocompatibility (Figure 12a).[297] The X-ray excited emission
shows strong peaks at 305 and 325 nm that match the absorp-
tion band of ZnO, facilitating effective energy transfer to generate
hydroxyl radicals in the presence of water via a Type I pathway)
(Figure 12b,c). This structure also shows a reduced oxygen depen-
dence; in vitro experiments in HeLa cells suggesting that there is
a comparable enhancement in ROS generation under normoxic
and hypoxic conditions. The in vivo treatments showed marked
reduction in tumors treated with SZNP and 8 Gy radiation (Fig-
ure 12d).
A recent publication suggests that suitable metal dopants (Zn,
Mn) in silicate act as nanoscintillators (ZSM) and produce visible
X-ray luminescence (450–900 nm);[298] this luminescence then
stimulates a conjugated PS, Rose Bengal (RB). This ZSM-RB con-
jugate was conjugated to RGD peptide forming RB-ZSM-RGD
that ensures high specific binding to the U87MG cells. The ROS
generation process was effective enough to create sufficient 1O2
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Figure 13. a) Formulation of RGD-ZSM-RB nanosensitizer. b) Live/dead cell imaging (green fluorescence for live cells, red fluorescence for dead cells)
of U87MG cells with different treatments (Scale bar, 100 µm). c) Western blot assays confirming the effect of X-PDT on DNA and membrane lipids. d)
Clonogenic cell survival as a function of X-ray dose. e) In vivo fluorescence images of tumor-bearing mice (at 2, 4, 8, 12, and 24 h post injection i.v. of
RGD-ZSM-RB. f) Biodistribution of RGD-ZSM-RB in main organs and tumor at different times after i.v. administration. g) Tumor growth curves (***: P
< 0.001). Reproduced with permission.[298] Copyright 2019, Wiley-VCH.
to kill U87MG human glioblastoma cells with 1 Gy of 50 KV X-ray
dose (Figure 13a,b). The in vitro X-PDT responses suggest that
RB-ZSM-RGD is a potential candidate for treating glioblastoma.
In vivo fluorescence imaging (Figure 13e) and the NP biodistribu-
tion (Figure 13f) confirm high accumulation of NP in cells (18%
injected dose per gram) after 8 h (Figure 13f). Significant tumor
reduction was shown in a U87MG model in mice with an intra-
tumoral dose of 20 mg kg−1 and X-ray activation (Figure 13g).
Table 3 lists inorganic nanoscintillators that have been re-
ported for in vivo and/or in vitro X-PDT. Organic scintillators for
X-PDT application remain largely unexplored.
6.2. Organic Nanoparticles Integrated with Photosensitizers
Advances in nanoscale drug formulations make it possible
to produce organic NPs comprising molecular PSs.[308] This
approach is frequently required in standard therapeutic use
of PSs, which typically have poor water solubility and low
biocompatibility.[309,310] NP formulations combined with tumor-
targeting ligands allow, in principle, to enhance tumor selectiv-
ity of PSs and limit their toxicity to healthy tissues. The PSs can
either be conjugated to or encapsulated in clinically-approved or-
ganic NPs[311] and biomolecules attached to the surface may then
enable targeted delivery. Examples of such formulations include
PLGA NPs and liposomes, while Au NPs and Si NPs have also
been investigated preclinically.[312–315]
6.2.1. PLGA
Polymer NP PLGA NPs are widely used for drug delivery,
bioimaging, and diagnostics[300,316,317] diagnostics. PLGA can en-
capsulate hydrophobic drugs and the NPs are themselves hy-
drophilic, which facilitates biodistribution.[318–320] The biodegrad-
ability of PLGA is due to hydrolysis of its ester linkages in the
presence of water, which produces glycolic and lactic acids that
can be safely metabolized.[321] In addition, the surface of PLGA
NPs can be modified with, e.g., PEG, which can further improve
biocompatibility and provide colloidal stability.[322–324] PLGA NPs
have been conjugated with folic acid (FA) to enhance specificity
to HCT116 colorectal cancer cells (Figure 14a).[392] The conju-
gation and encapsulation were confirmed by absorption spectra
(Figure 14b), and it was found that VP is stable inside the NPs
for several hours. X-PDT with these NPs showed efficient tumor
cell killing (67% compared with 26% for 4 Gy X-ray dose only).
6.2.2. Liposomes
Liposomes have also been used to deliver encapsulated PSs in X-
PDT. These are artificial spherical vesicles with an enclosed phos-
Adv. Sci. 2020, 7, 2003584 © 2020 The Authors. Published by Wiley-VCH GmbH2003584 (19 of 34)
www.advancedsciencenews.com www.advancedscience.com
Table 3. Summary of scintillating NPs used in X-PDT.
Nanoparticles (NPs) Photosensitizer (PS) Radiation conditions Targeted (yes/no) In vitro/
in vivo
Ref
CaF2-Tm PPIX 100 kV, 1.5 Gy No In vitro
[299]
CeF3 Verteporfin (VP) 6 MeV, 6 Gy No In vitro
[180]
Gd2O2S:Tb Photofrin II 130 kV, 20 mA, 15 min No In vitro
[291]
Gd2(WO4)3:Tb Merocyanine 540 (MC540) 160 kV, 5–8 Gy No In vivo
[300]
GdEuC12 micelle Hypericin (Hyp) Synchrotron SOLEIL
400 mA, 1015 photons
per second
No In vitro [301]
LaF3:Ce Protoporphyrin IX (PPIX) 90 keV, 0.5 Gy min





250 keV, 0.44 Gy min−1 No In vitro [237]





PPIX 90 kV, 0.5 Gy min−1 No In vitro [292]
LiGa5O8:Cr
(LGO:CR)@mSiO2
2,3-naphthalocyanine 50 kV, 70 µA, 5 Gy Yes: EGFR
targeting
In vivo [293]
LiLuF4:Ce@SiO2 Ag3PO4–Pt (IV) 6 MV, 4 Gy No In vivo
[303]
LiYF4@SiO2@ZnO ZnO 220 keV, 2–8 Gy No In vitro
[297]
NaGdF4:Tb3+ RB 80 kV 0.5 mA, 20 min No In vivo [304]
SrAl2O4:Eu
2+ (SAO)@SiO2 MC540 50 kV, 70 µA, 0–5 Gy No In vivo
[27,39]
SiC/SiOx nanowires (NWs) H2TCPP 6 MV, 2 Gy No In vitro
[305]
Sr2MgSi2O7:Eu
2+, Dy3+ PPIX 0–7 Gy Yes: Folic acid
targeted
In vitro [306]
Tb2O3@ SiO2 Porphyrin 44 kV, 40 mA, 5.4 mGy s
−1 No In vitro [307]










Faxitron RX-650 cabinet No In vitro [239]
pholipid bilayer structure NPs.[325] The aqueous core allows the
encapsulation of hydrophilic drugs, while the lipophilic bilayer
allows encapsulation of hydrophobic drugs.[326] Liposomes have
the potential to be engineered to release payloads upon external
triggering and thermosensitive-, pH-, magnetic-, and photosensi-
tive liposomes have been reported.[327,328] Liposomes can also be
modified with targeting agents such as folic acid, transferrin or
antibodies, to increase their specificity to cancer cells and min-
imize off-target effects.[312] Different types of PS, such as por-
phyrins, phthalocyanine, and VP have been encapsulated in li-
posomes and used in conventional visible-light-mediated PDT in
both preclinical and clinical settings.[326,329–339] It has also been
demonstrated that X-rays can directly activate VP loaded inside
liposomes to generate ROS;[282] a similar concept using linoleic
acid hydroperoxide molecule has also been reported.[340]
X-ray-activatable liposomes incorporating Au NPs (3–5
nm) and VP in the bilayer and a chemotherapy drug (doxoru-
bicin)) or gene-silencing oligonucleotide (PACIR antisense)
in the core have been described by Deng et al.[282] Under 6
MeV X-ray exposure the VP was activated and generated 1O2
that destabilized the liposome structure to release the Dox or
oligonucleotide in a controllable way. Although the VP is the
main source of ROS here, the Au NPs also generate some
ROS[169,341,342] and contribute to the overall efficacy[343] that was
demonstrated by the efficiency by gene silencing in vitro and
chemotherapy in vivo. This technology is illustrated in Figure 15.
6.3. Inorganic Nanoparticles Integrated with Photosensitizers
Inorganic NPs other than nanoscintillators have also been ex-
plored for X-PDT, including complex nanoformulations that can
be used in combination with ionizing radiation, either as a
radiosensitizer or to transfer energy to a PS or as a PS per
se. These various formulations can also be functionalized with
tumor-targeting moieties. Mesoporous silica NPs (MSNs) and
upconverting NPs (UCNPs), are also being investigated as po-
tential candidates for carrying PSs.[344] Their surface function-
alities and biocompatibilities allow controlled drug release and
targeted drug delivery.[345–348] Several reports discuss silica as an
efficient carrier for PDT drugs such as RB, PpIX, and Ce6[349–354]
and some of these were used in combination with scintillating
NPs.[27,293,297] For example, an effective multifunctional nanoth-
eranostic system was constructed using Gd-UCNPs (NaYF4:Yb
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Figure 14. a) Formulation of FA-PLGA-VP NPs. b) Schematic of cell uptake via FR-mediated endocytosis. c) Confocal image showing the uptake of FA-
PLGA-VP by HCT 116 cell lines at different incubation time. d) HCT116 and normal (CCD 841 CoN) cell kill for different X-ray doses using the targeted
NPs. e) X-PDT cell kill for different constructs and radiation doses. Reproduced with permission.[392] Copyright 2018, Dove Medical Press Ltd.
Figure 15. a) Illustration of X-ray assisted gene silencing and cancer cell killing. b) TEM image of liposomal NPs incorporating with Au NPs and VP.
c) Singlet oxygen generation measured by a fluorescent probe (SOSG) from various liposomal formulations. d,e) Antitumor activity of X-ray triggered
LipoDox in a xenograft model of colorectal cancer as measured by tumors volume d) and body weight e) after various treatments administered at the
time indicated by the arrow. f) Mean percent tumor necrosis for various treatments. Reproduced with permission.[282] Copyright 2018, Springer Nature.
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Figure 16. a) Representation and d) in vitro evaluation of synergetic chemo-/radiotherapy effects on HeLa cells after coincubation with free
Dtxl/UCMSNs-Dtxl. b) Representation and e) in vitro evaluation of synergetic radio-/photodynamic therapy after coincubation with UCMSNs-HP. c)
Representation and f) in vitro evaluation of synergetic chemo-/radio-/photodynamic therapy after coincubation with UCMSNs-HP-Dtxl. g) Tumor growth
following chemo-/radio-/photodynamic therapy on 4T1 tumor-bearing mice after intratumoral injection of UCMSNs-HP-Dtxl. h) Tumor growth after in-
travenous injection of UCMSNs-HP-Dtxl. i) In vivo T1eMRI images of a 4T1-tumor bearing mouse after intravenous injection of UCMSNs at designated
time points: (a) 0 min, (b) 5 min, (c) 10 min, and (d) 15 min. Reproduced with permission.[355] Copyright 2014, Biomaterials.
(18%)/Er(2%)/Tm (1%)) as the core and mesoporous silica as a
shell (UCMSN). A PS, hematoporphyrin (HP), and a chemother-
apy drug, docetaxel (Dtxl) were loaded to this NP.[355] The NPs
could be triggered either by ionizing radiation or by NIR through
energy transfer from the UCNPs. Figure 16a,d demonstrates
the synergetic chemo-radiotherapy effects on HeLa cells incu-
bated with UCMSN-Dtxl. Dtxl itself is a clinically approved
chemo/radiosensitizer drug but it has poor solubility that has
limited its efficacy. Here, the UCMSN-Dtxl showed enhanced
therapeutic effects compared to free Dtxl. Similarly, HP loaded
into UCMSN by covalent conjugation led to decreased tumor
cell viability after treatment with radiotherapy and NIR which
was (20%) was lower than with radiotherapy (32%) or NIR alone
(38%) (Figure 16b,e). However, codelivery of Dtxl and HP was
not more effective than individual delivery (Figure 16c,f). Fig-
ure 16g,h shows the in vivo results in a subcutaneous 4T1 breast
cancer model. This nanoconstruct can also be used as an MRI
contrast agent (Figure 16i).
Table 4 presents representative examples of all X-PDT nano-
materials in the literature. Comprehensive summaries have been
reported elsewhere.[39,356–360]
7. Clarification of Terminology Used in the Field
The boundaries of terms “radiosensitization,” “X-PDT,” and “ra-
diodynamic therapy” are somewhat fluid in the subject literature,
and we feel that they are worth discussing to avoid unnecessary
disputes.
With respect to radiosensitization, according to Gallez[370] it
is “a physical, chemical, or pharmacological intervention that in-
creases the lethal effects of radiation when administered in con-
junction with it.” Gallez describes only chemical and biologic
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Table 4. Representative NPs used in X-PDT.
Nanoparticles (NP) Photosensitizer (PS) Role of NP in X-PDT Radiation
conditions





Rose Bengal (RB) Radiosensitization and
energy transfer to PS




Au Verteporfin (VP) Prevention of aggregation of
PS and radiosensitization
6 MV, 6 Gy No In vitro [283]
Au@SNs PPIX Radiosensitization 6 MV, 2 Gy No In vivo [361]
BiOI@Bi2S3@BSA
(SHNP)
– Radiosensitization 50 kV, 80 µA, 6 Gy No In vivo [202]
CLC/SPIO micelles Ce6 Radiosensitization 6 MV, 2 Gy Yes: Folic acid targeted In vivo [362]
Cu–Cy Cu–Cy Radiosensitization 90 kV, 30 mA No In vivo [363]
GQDs PPIX Radiosensitization and
energy transfer to PS






Energy transfer to PS 120 kV, 20 mA No In vitro [351]
Hf-DBB-Ru DBB-Ru Ru(bpy)3











40 kV, 15 mA, dose
not specified
Nontargeted In vivo [365]
TiO2:C – Radiosensitization 80 kV 10 mA
0.08 Gy min−1
Nontargeted In vitro [366]
TiO2:Ce – Radiosensitization 80 KV, 10 mA,
0.08 Gy min−1 for
100 s
Nontargeted In vivo [367]
W IV doped
ZnGa2O4:Cr
ZnPcS4 Energy transfer to PS 50 kV, 60 µA, 0.18
Gy
Nontargeted In vivo [368]
ZnO MTCP and CuMTCP Energy transfer to PS 70 kV, 8 mA,
0.94 Gy for 30 s
Nontargeted In vitro [369]
response modifiers. The NCI Dictionary of Cancer Terms[371]
states that “radiosensitization is the use of a drug that makes
tumor cells more sensitive to radiation therapy.” The Medical
Dictionary[372] goes even further and states that radiosensitizer
is “a chemotherapeutic agent used to enhance the effect of radia-
tion therapy.” In this work we adopt a definition that radiosensi-
tization is a process of interference with cells to make cells more
sensitive to radiation. This interference with cellular processes
may take the form of increasing the amount of ROS generated
from a defined radiation dose or making cells more vulnerable,
by interfering with molecular targets in cells,[373] for example, by
disarming cellular antioxidant defences or exposing cells to radi-
ant heat, while the amount of ROS generated by radiation remain
unaffected. Clinically used radiosensitizers (Section 3.5) belong
to the latter category.
The term X-PDT refers to the method first introduced by Chen
and Zhang in 2006[38] who combined a nanomaterial with X-rays
resulting in generation of ROS. This process is also referred to
as X-ray mediated PDT or (rarely) PDT-X. X-PDT is defined as
the use of X-rays instead of UV–vis light in combination with PS
where the use of X-rays enables deeper penetration into tissue.
PS is an agent that generates ROS upon interaction with photons.
According to NCI Dictionary of Cancer Terms photosensitizer is
a drug (also called photosensitizing agent) used in photodynamic
therapy. When absorbed by cancer cells and exposed to light, this
drug becomes active and kills the cancer cells. Accordingly, in
this work we refer to X-PDT as combining materials (molecu-
lar, nanomaterials or their combinations) with X-rays to generate
ROS above and beyond what would be generated by the same
dose of X rays in the tissue. We note that the literature in the
area of X-PDT is predominantly focussed on designing various
nanomaterials which tend to play an active role to generate ROS
and not just act as carriers. We also emphasize that, according to
our definition, X-PDT is a special form of radiosensitization that
is drawing on mechanisms from physics, chemistry, and mate-
rials engineering approaches rather than on mechanisms in cell
biology. Furthermore, all X-PDT materials discussed here are ra-
diosensitizers.
The term radiodynamic therapy is used less frequently,[42] and
it typically refers to combining molecular PSs (or equivalent) with
X-rays. However, it is also used when molecular PSs are encapsu-
lated in NP carriers (such as polymer carriers) which do not—on
their own—generate additional reactive oxygen species when ex-
posed to X-ray radiation.
8. Future Directions for Materials Science in X-PDT
Free radical generation by NPs interacting with X-rays in con-
ditions compatible with clinical radiotherapy offers a potential
new option for cancer therapy. Generated in amounts over and
Adv. Sci. 2020, 7, 2003584 © 2020 The Authors. Published by Wiley-VCH GmbH2003584 (23 of 34)
www.advancedsciencenews.com www.advancedscience.com
Figure 17. Promising future directions for materials science in X-PDT.
beyond those produced by radiation alone, this approach offers
defined advantages. Most notably, X-PDT allows to overcome the
depth limitation of conventional photodynamic therapy using an
external light source.[28] By inducing free radicals at sub-clinical
radiation doses, X-PDT could provide an effective treatment of
deep-seated and larger solid tumors. The use of NPs allows these
free radicals to act alone, or in combination with other codeliv-
ered agents (oxygen sources, therapeutic drugs, genes, etc.), and
agents that may be modified or released by the free radicals, offer-
ing opportunities for new modes of action, such as precisely syn-
chronous delivery of drugs and radiation, with the potential for
synergistic action and multimodality. This is because nanomate-
rials can be endowed with a wide range of sophisticated function-
alities. Opportunities such as these have stimulated many groups
to publish in excess of 900 papers in the area which were cited
over 23 000 times. However, we feel that the research and down-
stream clinical opportunities are much wider and deeper than
what is pursued currently. With that in mind, this review dis-
cusses and indicates areas for future research opportunities and
potential clinical translation. It is widely recognized that the X-
PDT technology sits at the intersection of clinical radiation ther-
apy, photomedicine and nanotechnology. It also intersects with
tumor biology and pharmacology that have yet to be fully ex-
ploited to maximize the efficacy and safety of X-PDT. For exam-
ple, mainstream megavoltage X-rays have been mainly used in
X-PDT to date, with limited exploration of radioisotopes. How-
ever, high-LET radiation such as obtained with proton accelera-
tors is also emerging and could open up new avenues for X-PDT.
Complementing this, there are vast areas of nanotechnology that
currently seem unrelated to medical applications, such as pho-
tocatalysis, solar energy conversion, clean energy, environmen-
tal remediation, that have developed sophisticated solutions to
engineer NPs and their surfaces to optimize generation of free
radicals using light. Some of these approaches might be effective
when light is replaced by ionizing radiation, and examples have
been given in Section 6.
Furthermore, nanotechnology research has introduced many
options for sophisticated drug delivery, that can be applicable to
X-PDT and which offer unique advantages, including those high-
lighted in Section 6.2. However, the field is only beginning to ex-
plore the opportunities in relation to the agents and drugs that
can be codelivered with the free radicals generated during X-PDT.
There are also similar opportunities to incorporate inhibitors of
cellular processes driving the cellular response to radiation into
the X-PDT nanomaterials, as highlighted in Section 3.4, Even
more importantly, there is a possibility to use NP formulations to
deliver defined “cocktails” of clinically approved therapeutics, in-
cluding chemotherapy drugs and radiosensitizers. As addressed
in Sections 6.2.1 and 6.2.2, it is possible to use nanomaterial car-
riers built from clinically approved materials and to use clinically
approved PSs for X-PDT, which would accelerate clinical trans-
lation. Importantly, some of these carriers (Section 6.2.2) offer
unique opportunities for spatial and temporal control of drug de-
livery, for example, the patented technology for X-ray triggering
of liposomes.[282,374] These options are illustrated in Figure 17.
9. Potential and Challenges in Clinical Translation
of X-PDT
Successful[169] development of X-PDT, including the use of nano-
materials incorporating PSs and other clinical drugs and agents,
has high potential for clinical translation, particularly in oncol-
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Table 5. Challenges in clinical translation of X-PDT.
CHALLENGE
Fundamental Adequate cell kills at well-tolerated X-ray dose with systemic nanomaterials administration
Adequate nanoparticle tumor-to-normal selectivity and ensuring tumor specificity.
Acceptable toxicities: systemic, skin/ocular phototoxicity, unfavorable pharmacological profiles
Practical Overcoming biological barriers in nanoparticle delivery to cancer
Optimal time between nanoparticle administration and X-irradiation, accounting for cumulative uptake and clearance
Treatment planning incorporating nanomaterials uptake in individual patients
: dose algorithms and software
: nanoparticle uptake measurements in tumor and normal tissues
Clinical Trial(s) design
Adoption and integration into clinical practice: efficacy versus risks, cost, and complexity
Regulatory Controllability and manufacturing reproducibility and variations of nanoparticle formulations (nanoparticle heterogeneity,
aggregation, and dissociation)
Approvals for combination nanoparticle-radiation treatments: safety and efficacy
Commercial Feasibility and ownership of IP protection of nanoparticle formulations and X-PDT technologies
Cost-benefit as stand-alone modality or as radiation sensitizer
ogy. The opportunities will exploit many of the fundamental ad-
vantages and capabilities of the novel nanomaterials, as discussed
in this paper. This clinical translation falls into two broad cat-
egories that, while they may share aspects of the underlying sci-
ence, would be quite distinct in their clinical utilization: a) X-PDT
as a stand-alone therapeutic modality where X-rays stimulate a
systemically delivered traditional PS drug, and b) the use of NP,
NP PS or NP-PS-drug formulations (at the focus of this review)
as radiation sensitizers for conventional fractionated radiation
therapy. In both cases the methods of external-beam radiotherapy
would be employed while, analogously, radioactive sources could
be used as the energy source, either using systemically admin-
istered radionuclides as in radioimmunotherapy or implanted
solid sources as in brachytherapy.
The stand-alone approach would, ideally, involve the use of a
single X-ray exposure, or small number of fractions, with a total
X-ray dose that is much smaller than that used for conventional
radiotherapy, with the intent to destroy the tumor or to down-
stage the disease for subsequent additional therapies such as sur-
gical resection. As already indicated, compared with conventional
PDT using external (laser, LED) light sources, this would have
the advantage of enabling treatment of deep-seated and larger
tumors without the complexity of fiber-optic or endoscopic light
delivery.[87] In principle, the modality could be used either for pri-
mary solid tumors or for more disseminated disease, including
types of metastatic cancer which are technically very difficult or
impossible to treat using external light sources. X-PDT as a stand-
alone modality can also be expected to preserve some of the main
biological advantages of PDT,[140] that include low systemic tox-
icity, good healing of normal tissues and immune upregulation
that may contribute significantly to the treatment efficacy.[375] An-
other advantage of PDT is the ability to repeat the treatment as
often as required to sustain tumor control: however, this would
be impaired in X-PDT, as the X-ray exposure would be cumulative
and limiting.
In the second approach, the NP-PS-drug formulation would
be used to increase the tumor cell kill during conventional mul-
tifractionated radiotherapy or brachytherapy, i.e., as a novel form
of radiosensitization.[39,72] Recognizing that collateral damage
to normal tissues in the radiation field is often dose-limiting
in radiation therapy, tumor-selective radiosensitization[12,376] en-
ables either i) increased tumor response using the same dose
or ii) reduced normal tissue damage and resulting complica-
tions by using the same dose while maintaining the same tumor
response.
In addition to opportunities, there are many challenges in
translating X-PDT with these various NPs and formulations into
clinical oncology practice, including those listed in Table 5. First
and most critical in stand-alone X-PDT is to achieve a clinically
impactful efficacy at an X-ray dose that is well tolerated level by
normal tissues within the radiation field, say <10 Gy compared
to a typical fractionated radiotherapy dose of 50–70 Gy. It should
be noted that a very small amount of energy is required to cause
DNA strand breaks with X-rays, leading to proliferative cell death,
whereas light-activated PDT normally relies primarily on somatic
cell death mediated by damage to membrane structures.[375] For
example, a 50 Gy X-ray dose corresponds to an absorbed energy
of 0.05 J g−1 of tissue, whereas a typical incident surface light
irradiance in conventional PDT is ≈100 J cm-2 so that, assum-
ing the light is absorbed within 1 cm tissue thickness, the energy
absorbed is ≈100 J g−1, i.e., 3 or 4 orders-of-magnitude greater
than in radiotherapy. Hence, X-ray PDT will likely require some
form of biophysical or biological enhancement or amplification
to achieve comparable efficacy. Overcoming the energy barrier
by targeting the NPs to the cell nucleus[113–115] could provide the
necessary amplification, as has been shown with PDT itself.[377]
Molecular targeting of cancer and nuclear targeting would also
facilitate using systemic administration of the NPs, avoiding the
need for intratumoral injection to achieve very high local con-
centration that has been reported in some studies of X-PDT (e.g.,
as in Figure 6[198]) but is problematic to apply clinically. Using
X-PDT as a novel form of radiosensitization for conventional ra-
diotherapy also circumvents this energy problem, since the mod-
est increase in tumor cell kill per X-ray dose fraction reported in
several X-PDT studies (e.g., as in Figure 14) could still result in
significantly increased treatment efficacy:, e.g., 20% higher cell
kill per 2 Gy fraction translates to >2 logs of additional tumor
cell death after 30 fractions.
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A second major challenge is to achieve adequate tumor speci-
ficity of the NP complement the spatial targeting of the X-ray
beams. For example, in the radiosensitization case above, if the
tumor-to-normal tissue uptake is only 2:1, then the differen-
tial increase in tumor cell kill after 30 fractions drops to <20-
fold (1.230/1.130), assuming a linear dependence of this effect on
NP concentration in the cells. Active targeting of nanomaterials
to tumors, beyond the intrinsic EPR effect, has been discussed
above[18,19] and is the focus of other reviews.[378] These and other
authors review[11,43,379–381] and discuss biological barriers in tar-
geted NP delivery to tumors such as half-life of blood circulation,
or opsonization, and opportunities, e.g., engineering of tumor-
associated macrophages to act as a reservoir of nanotherapeu-
tics from which the drug payload is gradually released. From the
translational perspective, there is nothing particular in targeting
nanomaterials for X-PDT, except perhaps if additional subcellular
organelle targeting is required. Importantly, efficient and selec-
tive tumor targeting also enables the total dose of NPs adminis-
tered to the patient to be reduced, which addresses the third chal-
lenge of their potential toxicities. Again, the general topic of NP
toxicity has been reviewed in depth elsewhere[382] and the same
general issues arise, due both to the component organic and inor-
ganic materials (including, e.g., scintillation nanocrystals if used)
and to the nanoparticulate nature itself. Examples of toxicity man-
agement of nanomaterials including inorganic quantum dots is
reviewed by Corbo and co-workers,[383,384] while Liu et al. and Nel
et al.[385,386] discuss regulatory challenges for toxicity testing of
nanomaterials designed for clinical applications. Additional fac-
tors in NP-mediated X-PDT are the potential of damage to skin
or the eyes from light exposure of the PS component, which has
sometimes been a limiting toxicity in conventional PDT with
some PSs,[140] which has not been examined in X-PDT studies
to our knowledge.
At the practical level, particularly as a stand-alone treatment,
X-PDT in patients will require a treatment planning platform,
most likely implemented by extending current radiotherapy
systems[387] to incorporate information on the NP concentration
in tumor and normal tissues within the radiation field. In turn,
this raises the challenge of how the NP uptake will be determined
in individual patients, which is not usually a significant issue in
diagnostic applications but will be critical for X-PDT to be used
safely and effectively, at least in stand-alone mode.
From the clinical perspective, the design of human trials of
X-PDT will combine many of the same challenges as in conven-
tional PDT trials[388] as well as those of radiotherapy trials, and
will involve NP and X-ray dose escalation, with corresponding
assessment of tumor response and off-target effects. Ultimately,
clinical X-PDT is most likely to fall under radiation oncology in
order to access the existing equipment infrastructure and exper-
tise, whereas conventional PDT has mostly been used by sur-
geons, endoscopists, dermatologists, and ophthalmologists. Cor-
responding changes in education and training of radiation on-
cologists, radiation physicists, and technologists will be required,
as well as the infrastructure to administer the NPs safely. Opti-
mizing the timing between NP administration and X-irradiation
will be challenging and, where multiple X-ray fractions are em-
ployed, the clearance rate from the tumor and normal tissues will
determine the frequency of multiple NP injections, with corre-
sponding concern for potential cumulative toxicities. This would
be less of an issue if X-PDT were to be delivered in a small num-
ber of fractions, analogous to stereotactic body radiation therapy,
SBRT.[389] Ultimately, the efficacy of X-PDT will need to be high
enough to justify its added costs and logistical complexity for it
to be adopted into radiation oncology practice. As with any other
new medical technology, the cost-benefit will need to be suffi-
ciently favorable for it to be commercially viable.[390]
If these challenges can be overcome, then X-PDT offers excit-
ing opportunities for research and clinical innovation that could
make a real difference in cancer control. In parallel, there are
likely opportunities also outside oncology, just as PDT itself has
been investigated and applied to address a range of unmet clini-
cal needs.[391]
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